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INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO UNDERSTAND 
THE VIRULENCE AND BIOFILM FORMING MECHANISM OF SELECTED 
VANCOMYCIN-RESISTANT Enterococcus faecium 
 
ABSTRACT 
 
Vancomycin-resistant enterococcus (VRE) is an emerging nosocomial pathogen 
which causes outbreaks in hospitals worldwide. It is, therefore, important to understand 
the virulence and how this organism persists as a nosocomial pathogen. Whole genome 
sequencing (WGS) provides a wealth of information to elucidate the genetic relationship, 
virulence potential, and resistance factors of VRE. However, such genomic studies are 
lacking in Malaysia. Moreover, since enterococci are often recovered from difficult-to-
treat biofilm-mediated infections, a detailed study on the biofilm formed by VRE is useful 
to better understand its pathogenicity. The objectives of this study are to perform 
comparative genomics analysis on the four local vancomycin-resistant Enterococcus 
faecium (VREfm) and to elucidate the transcriptomic profile of biofilm cells in respect to 
the planktonic cells. Four VREfm strains were isolated from two fatal cases of nosocomial 
infections in a tertiary hospital in Kuala Lumpur. One of these strains (VRE2) was 
isolated from an index case (patient X), whereas the other three (VREr5, VREr6, VREr7) 
were isolated from different body sites of another patient (patient Y) at around one-week 
interval. WGS and comparative genomics analyses revealed that the four strains have 
different sequence types (STs), ST80 and ST203. Subsequent phylogenomic study 
showed that VREr5 was more closely related to VRE2, but was distantly related to VREr6 
and VREr7 derived from the same host. Moreover, the genomic contents of VREr5 was 
also more similar to VRE2. The genomic data and clinical records suggested that patient 
Y was most probably infected by multiple strains of different clones. Alternatively, the 
strain that infected patient Y (VREr5) could have derived from the same clone from 
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patient X (VRE2), given their high genomic similarity. The four local strains were 
multidrug resistant. All of them carried the vanA genotype and showed indistinguishable 
Tn1546 structure. Virulence profiling revealed that these strains harbored a total of 13 
virulence genes mainly associated with adherence and biofilm formation. The 
transcriptomic analysis focused on the initial stage of biofilm formation to examine genes 
that are involved during the transition from planktonic to biofilm cells. Differential gene 
expression analysis revealed that the up-regulated genes in biofilm cells involved mainly 
in adherence, plasmid replication, and carbohydrate metabolism. Genes that have been 
reported to negatively regulate biofilm formation, such as the quorum sensing systems, 
fsr and luxS, and a transcriptional regulator gene spx, were highly down-regulated. The 
unique bee homolog of VREr5 was found to be down-regulated, implying a negative 
association of this locus to biofilm formation in VREr5. The results obtained from the 
gene expression study clearly reflected the attachment stage of biofilm development, 
including the preparation to enter the maturation stage. In conclusion, this study has 
contributed to the understanding of the genetic basis and diversity of local clinical strains 
which can be helpful to control the spread of VRE. This study also provides insight into 
the molecular mechanism of biofilm formation in VRE which might be useful in the 
development of new drugs.  
 
                                                                                                                     
Keywords: Vancomycin-resistant enterococcus, comparative genomics, transcriptomics  
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INTEGRASI GENOMIK DAN TRANSKRIPTOMIK DALAM MEMAHAMI 
KEVIRULENAN DAN PEMBENTUKAN BIOFILEM DALAM Enterococcus 
faecium TERPILIH  
 
ABSTRAK 
 
    Enterococcus yang resistan terhadap vancomycin (vancomycin-resistant enterococcus 
atau VRE) adalah patogen nosokomial yang menyebabkan wabak di hospital-hospital di 
seluruh dunia. Oleh itu, pengetahuan mengenai  kevirulenan dan bagaimana organisma 
ini tegar sebagai patogen nosokomial adalah penting. Penjujukan Genome Kesuluruhan 
(whole genome sequencing, WGS) menyediakan pelbagai maklumat bagi mengkaji 
hubungan genetik, potensi  virulens, dan faktor-faktor resistan VRE. Namun begitu, 
kajian genomik tersebut masih kurang di Malaysia. Selain itu, enterococci sering 
diperolehi daripada jangkitan berkaitan dengan biofilem yang sukar untuk dirawat. Oleh 
itu, satu kajian terperinci mengenai biofilem yang dibentuk oleh VRE adalah berguna 
bagi lebih memahami pathogeniciti organisma ini. Objektif-objektif kajian ini adalah 
untuk melaksanakan analisis genomik perbandingan kepada empat Enterococcus 
faecium tempatan yang resistan terhadap vancomycin (VREfm) dan untuk mengkaji 
profil transkriptomik sel-sel biofilem yang berkait dengan sel-sel plankton. Keempat-
empat strain yang dikaji diperolehi daripada dua kes maut jangkitan nosokomial di 
hospital pengajian tinggi di Kuala Lumpur. Salah satu strain yang dikaji (VRE2) 
diperolehi daripada kes indeks (pesakit X) manakala tiga strain lain (VREr5, VREr6, 
VREr7) diperolehi daripada pesakit tunggal (pesakit Y), daripada bahagian badan yang 
berbeza sekitar selang satu minggu. WGS dan analisis perbandingan genomik 
menunjukkan bahawa keempat-empat strain mempunyai pelbagai jenis jujukan (ST) 
iaitu ST80 dan ST203. Kajian phylogenomic seterusnya menunjukkan bahawa VREr5 
lebih berkait rapat dengan VRE2 tetapi kurang berkait dengan VREr6 dan VREr7 yang 
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berasal daripada pesakit yang sama. Selain itu, kandungan genom VREr5 juga lebih 
serupa dengan VRE2. Data genomik dan rekod klinikal mencadangkan bahawa pesakit 
Y mungkin dijangkiti oleh pelbagai jenis klon yang berbeza. Sebagai alternatif, strain 
yang menjangkiti pesakit Y (VREr5) boleh diperolehi daripada klon yang sama seperti 
strain pesakit X (VRE2) memandangkan persamaan genomik yang tinggi. Semua strain 
yang dikaji mempunyai resistan terhadap pelbagai ubat. Mereka membawa genotip 
vanA dan mempunyai struktur Tn1546 yang sama. Profil virulens mendedahkan bahawa 
strain ini menangandungi tiga belas gen virulens yang berkaitan dengan perekatan dan 
pembentukan biofilem. Analisis transkriptomik berfokus kepada peringkat awal 
pembentukan biofilem bagi mengkaji gen-gen yang terlibat semasa peralihan dari 
plankton kepada biofilem. Analisis perbezaan expresi gen mendedahkan penglibatan 
gen “up-regulated”  dalam perekatan, replikasi plasmid, dan metabolisme karbohidrat 
dalam sel-sel biofilem. Gen-gen yang mempunyai pegawalan negatif terhadap 
pembentukan biofilem, seperti sistem kuorum sensing, fsr dan luxS dan transkripsi gen 
pengatur spx, adalah “down-regulated”. Di samping itu, homolog bee telah didapati 
“down-regulated”, mencadangkan bahawa locus ini mungkin tidak berkaitan dengan 
pembentukan biofilem bagi VREr5. Keputusan yang diperolehi daripada kajian 
transkriptomik menunjukkan  peringkat perekatan pembentukan biofilem termasuk 
persediaannya untuk memasuki peringkat matang. 
    Secara ringkasnya, kajian ini telah menyumbang kepada pemahaman asas genetik dan 
kepelbagaian genetik dalam strain klinikal tempatan. Pengetahuan ini boleh digunakan 
untuk mengawal penyebaran VRE. Kajian ini juga menyumbang kepada pengetahuan 
baru berkenaan mekanisme molekul pembentukan biofilem di dalam VRE yang 
mungkin berguna untuk pembuatan ubat baru. 
 
Kata Kunci: Enterococcus yang resistan terhadap vancomycin, genomik perbandingan, 
transkriptomik 
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CHAPTER 1: INTRODUCTION 
1.1 General Introduction 
Enterococcus faecium has been associated with several serious or life-threatening 
nosocomial diseases such as urinary tract infections, surgical-related wound infections, 
bacteremia, and endocarditis (Higuita & Huycke, 2014). As an opportunistic pathogen, E. 
faecium mainly targets elderly patients with underlying diseases, immunocompromised 
patients, and patients who have been hospitalized for prolonged periods or treated with 
invasive devices. The clinical significance of E  faecium becomes more prominent with 
the increasing antimicrobial resistance among the clinical isolates, including high-level 
resistance to ampicillin, aminoglycosides, and glycopeptides (Cattoir & Giard, 2014; 
Leclercq et al., 1988; Padmasini et al., 2014; Uttley et al., 1988). The rapid spread of 
vancomycin resistant E. faecium (VREfm) is of particular concern as VRE is often 
multidrug resistant. According to a recent report from the National Healthcare Safety 
Network (NHSN), 82.2% and 85.1% of enterococci recovered from bloodstream and 
urinary tract infections are resistant to vancomycin in the year 2014 (Sievert et al., 2016). 
The emergence of VRE and outbreaks that occur around the world indicate the success of 
E. faecium in adapting to and surviving in the hospital environment. Worryingly, resistance 
to antibiotics that are used to treat VRE infections, such as linezolid, daptomycin, and 
tigecycline, has been reported (Edelsberg et al., 2014; Tsai et al., 2012).  
With the rapid advances in next generation sequencing (NGS) technology, different 
NGS platforms such as Roche/454, SoLiD, and Illumina enable the entire genomes of 
bacterial pathogen including E. faecium to be sequenced (Lam et al., 2013, 2012; Qin et 
al., 2012).  This technology generates massive information that is helpful in exploring the 
differences between strains of E. faecium at a genome-wide level. The whole genome 
sequences obtained can, therefore, provide an in-depth understanding of the genetic 
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contents, resistance determinants and mechanisms, as well as pathogenicity and evolution 
of E. faecium. This information is important in revealing factors that contribute to its 
adaptation and persistence in the clinical settings, and, hopefully, solutions to control and 
treat infections. To date, a number of genome sequences of E. faecium have been reported 
(García-Solache & Rice, 2016; Khan et al., 2015; Lam et al., 2013, 2012; Qin et al., 2012).  
Genome analyses revealed that clinical isolates are different from non-clinical isolates in 
that the number of mobile genetic elements, resistance and virulence genes are 
significantly higher in the genomes of clinical isolates (Kim & Marco, 2014; Qin et al., 
2012). Apart from that, specific elements such as the esp gene and IS16 are found almost 
exclusively in the hospital-associated isolates (Heikens et al., 2012; Leendertse et al., 2009; 
Werner et al., 2011; Willems et al., 2001). The findings from these genomic analyses have 
shed light on the virulence and persistence of clinical E. faecium which is important in 
controlling the spread of this nosocomial pathogen.  
The clinical relevance of infections caused by VREfm can also be attributed to the 
difficult-to-treat biofilm-associated diseases. It has been reported that majority of the 
device-associated infections, such as infections due to central lines, urinary catheters, and 
ventilators, are caused by VREfm (Sievert et al., 2016). Since biofilms are highly resistant 
to antibiotics and phagocytosis, a detailed insight into the process and molecular 
mechanism of biofilm formation is pivotal for the development of new drugs against 
biofilm-mediated infections. Transcriptomic analysis enables the quantification of gene 
expression of a full transcriptome, thereby help in interpreting the functional elements of 
a genome that are expressed at a specific physiological condition or developmental stage 
(Wang et al., 2009). The introduction of RNA-seq technology provides a more sensitive 
and dynamics approach to study the transcriptome of various organisms as compared to 
the traditional hybridization method (microarray) (Hinton et al., 2004; Wang et al., 2009). 
In the case of biofilm formation, this high-throughput technology has generated 
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informative data which is helpful in understanding the molecular mechanisms of biofilm 
biogenesis that are important for drugs development (Rumbo-Feal et al., 2013; Tan et al., 
2015).  
 
1.2 Objectives 
To the best of our knowledge, a complete genome analysis of clinical VREfm has not 
been reported in Malaysia. Hence, such study is needed to better understand the overall 
biology, and the potential resistance and virulence of the locally isolated VREfm strains. 
Moreover, transcriptomic studies on the biofilm formation of E. faecium is also lacking in 
Malaysia or Southeast Asia. Understanding the transcriptome of biofilm cells is important 
in the development of new control or treatment methods against biofilm-mediated 
infections. 
Therefore, the objectives of this study were: 
1. To perform comparative genome analyses of four selected VREfm from Malaysia; 
2. To elucidate the gene expression profile of biofilm cells in respect to the planktonic 
cells. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 The Genus Enterococcus 
The genus Enterococcus was previously classified as part of the genus Streptococcus. 
It is not until 1984 when the Enterococcus was recognized as a separate genus (Schleifer 
& Kilpper-Balz, 1984). Streptococcus faecalis and Streptococcus faecium were the first 
two species to be transferred to the new genus as Enterococcus faecalis and Enterococcus 
faecium. To date, there are more than 50 species of enterococcus being described 
[http://www.bacterio.net/index.html].  
Enterococci compose of Gram-positive cocci that are often arranged in pairs or chains. 
They are catalase-negative, non-spore-forming facultative anaerobes which can survive in 
harsh conditions, including high salinity (6.5% NaCl) and a wide range of temperature 
(10°C to 45°C) (Facklam & Collins, 1989). As such, enterococci are ubiquitous in nature. 
They can be found in water, soil, plants, as well as fermented food and dairy products. 
Enterococci are also commensals in the gastrointestinal tracts of human and animals. 
Although accounted for only 1% of the human gut microflora (Sghir et al., 2000), 
enterococci can occasionally cause diseases such as urinary tract infection and 
endocarditis, especially in immunocompromised patients.  
 
2.2 Emergence of vancomycin-resistant enterococci (VRE) 
Enterococci have long been considered as harmless inhabitants of the human gut flora. 
However, in the past few decades, this organism has emerged as one of the leading cause 
of hospital-associated infections. The extensive use of antibiotics in the clinical settings 
has contributed remarkably to the transition of this organism from commensal to the 
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nosocomial pathogen. Following the development of resistance to beta-lactam drugs and 
to high concentration aminoglycosides in the 1980s, vancomycin was among the last 
available antibiotic for enterococcal infections.   
Vancomycin acts by disrupting cell wall synthesis. Once enterococci get in contact with 
the compound, vancomycin binds to the D-ala-D-ala terminus of the peptidoglycan 
precursor, thereby inhibiting cell wall development (Courvalin, 2006). Due to its disruptive 
effect on peptidoglycan, vancomycin is commonly used together with other antibiotics 
such as aminoglycosides to effectively get rid of the pathogen. Although the use of 
vancomycin has successfully controlled enterococcal infections, it was later discovered 
that the acquisition of vancomycin resistance has become increasingly prevalent (Bonten 
et al., 2001; Kuo et al., 2014).  
Vancomycin-resistant enterococci (VRE) was first reported in Europe in the 1980s 
(Leclercq et al., 1988; Uttley et al., 1988). Since then, VRE has spread worldwide, 
including in the United States, Europe, and East Asia regions (Bonten et al., 2001; Kuo et 
al., 2014). In Malaysia, the first confirmed case of hospital acquired VRE was reported in 
2006 in Hospital Kuala Lumpur (HKL) in a patient with chronic renal failure (Zubaidah et 
al., 2006). Other local studies reported a low prevalence of VRE (1-2%) in Malaysia 
(Ibrahim et al., 2010, 2011). A study collecting enterococci from different countries shows 
that vancomycin resistance was more prevalent in E. faecium (Putnam et al., 2010). A 
similar result was observed by Edelsberg et al. (2014) who examined resistance percentage 
of clinically significant bacterial pathogens in 19 US hospitals. The higher rate of 
vancomycin resistance in E. faecium indicates the increasing clinical importance of this 
organism over the other enterococcal species.  
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The use of avoparcin had been suggested to contribute to the dissemination of 
vancomycin resistance in E. faecium. This correlation can be shown through the different 
epidemiology of VRE in Europe and the United States. In Europe, where avoparcin was 
massively used as a growth promoter in animal farms (Wegener, 1998), VRE are more 
prevalent in livestock and healthy people compared to patients (Devriese et al., 1996; 
Stobberingh et al., 1999; Van Braak et al., 1998). However, this type of community-
reservoir in animals and healthy people is not observed in the United States, where 
avoparcin is banned in the animal farms. In contrast, VRE are the second most common 
nosocomial pathogen in the United States (Sievert et al., 2016). Since avoparcin can confer 
cross-resistant to vancomycin (Bager et al., 1997), the extensive use of this antibiotic in 
the animal farms may select for vancomycin resistant strains. Ultimately, these resistant 
strains could be transmitted to human through the food chain or to the farm workers due 
to poor hygiene practice in the animal farms. The possible association of avoparcin and the 
dissemination of vancomycin resistance was further strengthened by the reduction of VRE 
rate in Europe after the ban of avoparcin in 1997 (Aarestrup et al., 2001; Boggard & 
Stobberingh, 2000).  
There is evidence indicating that glycopeptide-producing microorganisms, such as 
Amycolatopsis orientalis and Streptomyces toyocaensis, are the sources of vancomycin 
resistance genes (Marshall et al., 1997). The production of these resistance genes is 
presumed as a self-defence mechanism of these organisms. These resistance genes then 
can be transferred horizontally via one or more bacterial intermediates, ultimately to 
enterococci. In the case of Europe, resistance gene may ultimately be transferred to 
genogroups that colonize animals and healthy people, resulted in a large community-based 
reservoir. On the contrary, in the United States, vancomycin resistance gene may be 
transferred to genogroups which had been resistant to multiple antibiotics, thereby 
7 
    
increasing the chance of acquired resistance due to the selective effects of antibiotics 
(Bonten et al., 2001).  
2.3 Molecular subtyping of E. faecium 
For many years, majority of the human enterococcal infections were caused by E. 
faecalis (80-90%) (Jones et al., 2004; Moellering, 1992). However, in the past three 
decades, E. faecium has increasingly become predominant as a leading cause of hospital-
acquired infections, particularly vancomycin-resistant E. faecium (VREfm). As such, 
molecular subtyping is important for epidemiological studies to assist in infection control 
as well as to trace the dissemination of this pathogen. Various subtyping methods have 
been developed for E. faecium. These include repetitive element sequence (REP)-PCR 
typing, plasmid typing, pulsed-field gel electrophoresis (PFGE), amplified fragment length 
polymorphism (AFLP), multiple locus variable number of tandem repeat analysis 
(MLVA), and vancomycin resistance gene cluster typing. However, each of these typing 
methods has its own drawbacks, mainly in terms of the ease of use, discriminatory power, 
cost, data reproducibility, as well as data exchange (Werner, 2013).  
PFGE is a highly discriminative typing method that can distinguish strains of the same 
species from different sources, time, and space. This macrorestriction-based typing method 
utilizes rare-cutting enzymes to fragment chromosomal DNA, and an alternating electric 
field (i.e. pulsed field) to separate the resulting DNA fragments, generating distinct 
patterns which can be used to differentiate closely related bacteria. Due to its high 
discriminatory power, PFGE remains a “gold standard” for epidemiological studies of a 
large number of bacteria, including E. faecium. However, since the rate of recombination 
is relatively high in enterococci (Willems et al., 2005), extreme genomic variations may 
be found in strains from the same outbreak over a period of time. As such, PFGE is less 
suitable for long-term epidemiological study of enterococci. Apart from that, inter-
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laboratory transfer of PFGE data is challenging as a standardized protocol of enterococcal 
PFGE has not been established.  
Multi-locus sequence typing (MLST) is a recently widely accepted typing method for 
population and evolutionary study (Urwin & Maiden, 2003). This method determines the 
alleles of the internal fragment sequences of multiple housekeeping genes and assigns each 
allele a numerical value. In E. faecium, seven housekeeping genes, atpA, ddl, gdh, purK, 
gyd, pstS, and adk, are used (Homan et al., 2002). The combination of the seven allelic 
numbers yields a sequence type (ST) that classifies different strains. MLST allows for the 
exchange of data throughout the globe through the use of uniform typing method and the 
establishment of a large, publicly accessible database. However, this method can be 
relatively costly if sequencing of the seven housekeeping genes of a large number of 
samples is to be performed.  
A distinct clonal lineage comprised of mostly clinical E. faecium isolates was identified 
when the MLST data was analyzed using the enhanced based upon related sequence types 
(eBURST) algorithm (Willems et al., 2005). This lineage is termed clonal complex 17 
(CC17). Members of the CC17 are characterized by ampicillin resistance, a pathogenicity 
island and an association with hospital outbreak (Willems et al., 2005). Shortly, this lineage 
turns into the major genetic complex associated with hospital infections and is found to be 
disseminated around the world (Matsushima et al., 2012; Ryan et al., 2015; Valdezate et 
al., 2009; Yu et al., 2015).  
 
2.4 Whole genome sequencing of E. faecium 
The increased medical importance of E. faecium over E. faecalis as a nosocomial 
pathogen drives interest into the epidemiology and pathogenicity of this organism. 
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However, there are still gaps in our understanding of its virulence, pathogenicity, resistance 
mechanisms, and even adaptability. The availability of whole genome sequencing (WGS) 
allows scientists to explore in more detail the biological features of E. faecium to provide 
answers to the emergence of this pathogen. 
The first complete genome of E. faecium was available in March 2012 from a 
vancomycin-resistant strain Aus0004. Aus0004 was isolated from the bloodstream of a 
patient in Melbourne, Australia, in 1998 (Lam et al., 2012). Following this, the second 
complete genome was published by (Qin et al., 2012) and was determined by strain TX16 
(also named TX0016 or DO) isolated from the blood of an endocarditis patient in 1992. 
More genomes were later being published, which provide chances for comparative 
genomics to unveil the genomic variations among strains from different niches.  
There are currently more than 400 publicly available E. faecium genomes, with 17 
genomes being completely sequenced 
(https://www.ncbi.nlm.nih.gov/genome/genomes/871?). However, an overrepresentation 
of strains from Europe and North America is observed. Hence, more genomes from strains 
of various regions, such as from the Southeast Asia, are needed to fully understand the 
global diversity of E. faecium.  
 
2.5 Comparative genomics  
2.5.1 Core and accessory genome  
Genome comparison between several E. faecium strains has identified a set of genes 
known as “core” genome that are conserved in all strains. This core genome consists of 
genes that are mainly responsible for housekeeping functions such as DNA and carbon 
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metabolism, cell structural biosynthesis, and substrate transport. The non-core genes make 
up the “accessory” genome which are partially shared or strain-specific. These accessory 
genes may contribute to specific adaptive traits or even pathogenicity of different strains 
from different environmental niches. For instance, comparative analyses have revealed 
differences in genome content between the clinical and non-clinical strains. The genome 
of clinical strains composes of significantly more mobile genetic elements, virulence 
factors and antibiotic resistance genes compared to that of non-clinical strains (Kim & 
Marco, 2014). The esp gene, encodes for the enterococcal surface protein (Esp) which is 
associated with endocarditis and urinary tract infections, is specifically enriched in the 
clinical strains (Heikens et al., 2012; Leendertse et al., 2009; Willems et al., 2001). 
Moreover, acquired antibiotic resistance genes, such as van gene that confers vancomycin 
resistance, are also part of the accessory genome of clinical E. faecium strains.  
Several studies suggested that the pan-genome of E. faecium is open, indicating that this 
organism is able to acquire and incorporate novel genes efficiently into the collective gene 
pool of the species (Qin et al., 2012). This helps to explain the accumulation of a large 
number of accessory genes in the clinical strains that contribute to their pathogenicity. An 
open pan-genome also implies that E. faecium can readily acquire new genes that 
contribute to fitness, allowing it to adapt to various environmental niches, which might 
facilitate its transition from commensal to nosocomial pathogen. 
 
2.5.2 Insertion sequence, phage, and CRISPR 
Insertion sequence (IS) elements are short DNA fragments (0.7-2.5kb) that usually 
encode for one or two genes needed for transposition (Siguier et al., 2015). These elements 
are widely spread in bacterial genomes and are abundantly found in the genome of E. 
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faecium (Lam et al., 2013, 2012; Mikalsen et al., 2015; Qin et al., 2012). IS elements can 
play a vital role in evolution and diversification of genomes. IS16, for example, is almost 
exclusively present in the hospital-associated (HA) strains and was suggested as a marker 
for identification of HA E. faecium strains (Werner et al., 2011). Furthermore, 
transposition of IS elements can also lead to gene rearrangement such as duplication, 
deletion, and inversion, which contributes to genome plasticity among the species (Lee et 
al., 2016; Ooka et al., 2009). Apart from that, there have been evidence showing that IS 
elements can affect gene expression (Aubert et al., 2003; Sóki et al., 2013). In E. faecium, 
for example, insertion of IS elements in the vancomycin resistance gene cluster has led to 
reduced resistance in certain VRE strains (Gagnon et al., 2011).  
Bacteriophage (phage) is another mobile genetic element which can also drive genome 
diversification. Phages integrated into the bacterial genomes (prophages) can introduce 
new genes that modify the genome content of strains within the species. A number of 
prophages have been identified in the genome of E. faecium (Lam et al., 2013, 2012; Qin 
et al., 2012; van Schaik et al., 2010). These prophages are distinct from strain to strain, 
demonstrating phage diversity of E. faecium (Lam et al., 2013). In a comparison between 
seven E. faecium strains, van Schaik et al. (2010) reported that most of the phages 
identified can be activated by the DNA cross-linking agent mitomycin. These induced 
phages had the typical morphology of Siphoviridae, which is a common bacteriophage 
family found in lactic acid bacteria. It remains to be determined to what extent prophages 
contribute to the fitness of E. faecium but the variety of prophages identified suggest that 
they play a major role in shaping the genome of E. faecium. Nevertheless, phages may aid 
in the transmission of antibiotic resistance genes among enterococci species, as reported 
by Mazaheri Nezhad Fard and his co-workers (Mazaheri Nezhad Fard et al., 2011).  
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Clustered regularly interspaced short palindromic repeats (CRISPR) are short repetitive 
DNA sequences that are found in both archaea and bacteria. These repeats are 
characterized by direct repeats of varying size interspaced by non-repetitive sequences of 
a similarly size known as “spacer” and flanked on one side by a conserved leader sequence 
(Jansen et al., 2002). The CRISPR loci are usually associated with genes known as 
CRISPR-associated (cas) genes which encode for nucleases or proteins involved in DNA 
and RNA processing. This CRISPR-cas system has been shown to provide bacteria with 
adaptive immunity against the integration of foreign genetic materials such as phages and 
plasmids (Marraffini & Sontheimer, 2011). CRISPR-cas system appears to be found less 
frequently in the HA strains, which are usually multidrug resistant (Palmer & Gilmore, 
2010). This observation is consistent with the defensive role of CRISPR-cas system to 
limit the acquisition of mobile genetic elements which might carry antibiotic resistance 
genes. The absence of CRISPR-cas system in HA strains also explains the abundance of 
phages and other mobile elements in their genomes, highlighting the lack of barriers to 
horizontal gene exchange in the species.  
 
2.5.3 Virulence factors 
Comparison between the genomes of hospital-associated (HA) and community-
associated (CA) strains reveals several virulence factors that are enriched in the HA strains. 
The most significant one being the presence of esp gene which is found more abundantly 
in the clinical isolates than in food or environmental isolates (Abriouel et al., 2008; 
Willems et al., 2001). The esp gene was initially suggested to involve in initial adherence 
and biofilm formation in E. faecium (van Wamel et al., 2007). These roles were later 
proven by a biofilm deficient esp insertion-deletion mutant (Heikens et al., 2007). 
Subsequent studies using animal models indicate the association of esp to urinary tract 
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infections and endocarditis (Heikens et al., 2012; Leendertse et al., 2009). The esp gene of 
E. faecium is located on a large transferable pathogenicity island (PAI) which ranges from 
64 to 104 kb in size (van Schaik et al., 2010). Comparative genomics of three clinical E. 
faecium strains reveals that although the general architecture of esp PAI is conserved in all 
the three studied strains, variations are observed in the gene content of the PAI which are 
likely caused by the independent acquisition of genes through horizontal gene transfer (van 
Schaik et al., 2010).  
A putative virulence gene hylEfm was also found to be highly prevalent in clinical E. 
faecium strains (Freitas et al., 2010; Rice et al., 2003; Soheili et al., 2014). The hylEfm gene 
was initially suggested to encode for hyaluronidases but was later annotated as a putative 
glycoside hydrolase based on sequence comparison with spy1600 gene in Streptococcus 
pyogenes (Rice et al., 2003; Sheldon et al., 2006). It has been previously shown that the 
hylEfm gene is carried on transferable megaplasmids which can also carry genes conferring 
resistance to glycopeptides (Arias et al., 2009; Freitas et al., 2010). Some of these hylEfm-
containing plasmids have been shown to enhance gastrointestinal colonization and increase 
virulence in an experimental peritonitis mouse model, implicating potential virulence of 
the hylEfm gene in E. faecium (Arias et al., 2009; Rice et al., 2009). However, a more recent 
study demonstrates that hylEfm does not mediate the increased virulence conferred by the 
hylEfm-containing plasmid in murine peritonitis (Panesso et al., 2011). It remains to be 
determined if hylEfm plays any role in other infections such as endocarditis or urinary tract 
infections.  
In addition to esp and hyl, several virulence factors associated with surface adhesion 
and biofilm formation are also significantly enriched in the HA strains. These include the 
acm gene encoding a collagen adhesin, and several pili genes, such as the ebpABC locus 
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and fms21-fms20 locus. These virulence factors will be discussed in detailed in the biofilm 
section. 
 
2.6 Antibiotic resistance in E. faecium  
The clinical importance of E. faecium can be linked to its resistance to a broad range of 
antibiotics, which can be either intrinsic or acquired. Among all, acquisition of 
glycopeptides resistance, particularly to vancomycin, is the most significant event 
contributing to the transition of E. faceium from commensal to nosocomial pathogen.  
Glycopeptides inhibit bacterial growth by disrupting cell wall synthesis. Resistance to 
glycopeptides is caused by either elimination of the high-affinity peptidoglycan precursors 
originally produced by the host, which removes the target sites; or modification of the 
termini of peptidoglycan precursors from D-Ala-D-Ala to either D-Ala-D-Lac or D-Ala-
D-Ser, which lowers the binding affinity of the antibiotics to the target sites (Courvalin, 
2006; Guzman Prieto et al., 2016; Hollenbeck & Rice, 2012). To date, nine distinct gene 
clusters (vanA, vanB, vanC, vanD, vanE, vanG, vanL, vanM, and vanN) conferring 
glycopeptides resistance have been described in enterococci (Boyd et al., 2008; Courvalin, 
2006; Lebreton et al., 2011; Xu et al., 2010), with vanA and vanB being the most 
predominant gene clusters found in clinical VREfm.  
The vanA gene cluster confers a high-level resistance to vancomycin and teicoplanin. 
This cluster is typically encoded on Tn1546 or related transposons and consists of seven 
genes. The vanR and vanS genes encode for a two-component regulatory system which 
regulates the expression of vanHAXYZ. The vanH gene encodes for a dehydrogenase 
which converts cellular pyruvate to D-Lac. The vanA-encoding ligase then links the D-
Lac to D-Ala, creating the D-Ala-D-Lac depsipeptide which will later ligate to the 
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tripeptide precursor by host enzymes, yielding the low-affinity pentapeptide precursor. 
For a full resistance to vancomycin, elimination of normal precursors is required. This is 
done by vanX and vanY genes. vanX encodes a D-D-dipeptidase which hydrolyses the 
original D-Ala-D-Ala dipeptide, making D-Ala-D-Lac the sole substrate for 
peptidoglycan synthesis. On the other hand, vanY encodes a D-D-carboxypeptidase 
which eliminates the terminal D-Ala from the normal pentapeptides, rendering them 
useless for normal cell wall synthesis (Courvalin, 2006; Hollenbeck & Rice, 2012). The 
vanZ gene encodes for a protein with yet unknown function. However, an association of 
VanZ with low-level teicoplanin resistance had been documented before (Arthur et al., 
1995). Additionally, the vanA cluster also includes two genes (orf1 and orf2) which are 
responsible for transposition.  
Figure 2.1: VanA-type vancomycin resistance mechanism. A) Normal cell wall 
synthesis pathway and disruption of the pathway by VanX and VanY. B) Construction of 
a modified cell wall that is resistant to vancomycin. Figure adapted from Hollenbeck and 
Rice (2012). 
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Studies that characterized the vanA gene clusters of E. faecium from different 
geographical regions and sources revealed great structural variations of the Tn1546-like 
elements that are mainly caused by point mutations, deletions and IS insertions 
(Hashimoto et al., 2000; Huh et al., 2004; Kuo et al., 2014; Willems et al., 1999). Most 
of these modifications are observed in the genes that are not involved directly in 
vancomycin resistance (orf1, orf2, vanY, vanZ) and in the intergenic regions. Notably, 
insertion of IS1216V, IS1542, and IS1251, as well as truncation of the orf1 are the most 
frequently observed events (Gu et al., 2009; Huh et al., 2004; Kuo et al., 2014; Schouten 
et al., 2001). Some of these structural changes, especially those caused by IS integrations, 
have been shown to contribute to changes in the vancomycin and teicoplanin resistance 
level (Gagnon et al., 2011; Gu et al., 2009; Hashimoto et al., 2000; Sivertsen et al., 2016). 
Despite its high diversity, similar vanA cluster variants has been found in strains from 
different geographical regions and sources (human, animals, environments), indicating 
possible horizontal spread of the vancomycin resistance elements through conjugative 
plasmids or as part of a larger mobilized genetic unit (Huh et al., 2004; Sletvold et al., 
2010; Willems et al., 1999). In fact, polymorphism of the vanA gene cluster has been used 
as a typing tool which, coupled with epidemiological data, provides a better 
understanding on the dissemination of vancomycin resistance in E. faecium (Xu et al., 
2011).  
Unlike the vanA gene cluster, the vanB gene cluster confers moderate to high-level 
resistance to vancomycin, but not to teicoplanin (Hollenbeck & Rice, 2012). The VanB 
locus is usually found on Tn1549-like transposons, which are encoded on plasmid or 
chromosome. The genetic organization and resistance mechanism of VanB locus is 
similar to that of VanA locus. Homologs of VanH (VanHB), VanX (VanXB), VanY 
(VanYB), and VanA (VanB) are found in the VanB locus. Genes encoding the two-
component regulatory system in the VanB locus (vanRB and vanSB) are only distantly 
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related (34% and 24% amino acid identity, respectively) to the vanRS found in the VanA 
locus (Evers & Courvalin, 1996). This VanRSB system regulates differently from its 
counterparts of the Tn1546 in that only vancomycin, but not teicoplanin, induces 
resistance of the VanB locus (Evers & Courvalin, 1996). Apart from that, a gene related 
to vanZ is lacking in the VanB locus but an additional vanW gene with unknown function 
is found. Based on sequence analysis, three vanB subtypes (vanB1, vanB2, vanB3) are 
identified. However, there is no correlation between the different genotypes and the level 
of resistance to vancomycin (Dahl et al., 1999).  
High-level resistance to ampicillin is another important feature of clinical E. faecium. 
Ampicillin, like other beta-lactams, binds covalently to the penicillin-binding proteins 
(PBPs) and disrupts cross-linking of peptidoglycan precursors, thereby impairing cell 
wall synthesis. E. faecium exhibits intrinsic resistance to ampicillin due to the expression 
of low-affinity penicillin-binding protein 5 (PBP5). Increased resistance to ampicillin is 
mediated by either acquisition of beta-lactamase or mutations in the pbp5 gene 
(Hollenbeck & Rice, 2012). In E. faecium, high-level ampicillin resistance is mainly due 
to the accumulation of various point mutations in the penicillin binding regions of PBP5 
(Galloway-Peña et al., 2011; Rice et al., 2004). A combination of two point mutations, a 
methionine-to-alanine change in position 485 and an insertion of serine at position 466 of 
pbp5, has been shown to markedly enhance ampicillin resistance (Rice et al., 2004). A 
later study showed that the chromosomally encoded pbp5 is able to transfer among E. 
faecium strains through conjugation (Rice et al., 2005). This suggests that mutated pbp5 
with enhanced resistance could be transmitted in the same way among the clinical 
isolates. On the other hand, high-level ampicillin resistance due to overproduction of beta-
lactamase is relatively rare in E. faecium compared to in E. faecalis (Hollenbeck & Rice, 
2012).  
18 
    
Another group of antibiotics to which E. faecium exhibits intrinsic and high-level 
acquired resistance to is aminoglycosides. Aminoglycosides act by inhibiting ribosomal 
protein synthesis. Generally, all enterococci are intrinsically resistant to low-level of 
aminoglycosides due to poor uptake of the antibiotics (Bryan & Van Den Elzen, 1977). 
The combination of cell-wall active agents such as ampicillin or vancomycin with 
aminoglycosides increases the uptake of the antibiotics, thereby enhances the killing 
effect on enterococci (Moellering & Weinberg, 1971). Other than the natural uptake 
barrier, E. faecium also poses chromosomally encoded enzymes such as 6′-N-
aminoglycoside acetyltransferase encoded by aac(6′)-Ii and rRNA methyltransferase 
encoded by efmM that confer low to moderate intrinsic resistance to aminoglycosides 
(Hollenbeck & Rice, 2012).  
The acquisition of various genes encoding aminoglycoside-modifying enzymes 
(AMEs) results in high-level aminoglycosides resistance in E. faecium, which abolish the 
synergistic killing effect that is important for the treatment of severe enterococcal 
infections. The bi-functional gene aac(6´)-Ie-aph(2´´)-Ia is the most clinically significant 
as strains carrying this gene is virtually resistant to all clinically available 
aminoglycosides except streptomycin (Chow, 2000). aac(6´)-Ie-aph(2´´)-Ia is the most 
prevalent gene that confers high-level gentamicin resistance in enterococci, although 
other genes such as aph(2´´)-Ib, aph(2´´)-Ic, and aph(2´´)-Id also confer resistance to 
gentamicin (Chow, 2000). The enzymes encoded by aac(6´)-Ie-aph(2´´)-Ia inactivate 
gentamicin by phosphorylating the 2´ hydroxyl position of gentamicin (Ferretti et al., 
1986). This modification renders the antibiotic unable to bind to its target on the 30S 
ribosome, thereby loses its antibacterial activity. Streptomycin can be used in the 
synergistic therapy against enterococci when aac(6´)-Ie-aph(2´´)-Ia is present,  provided 
that there is no resistance to high levels of streptomycin (MIC ≥ 1000 μg/ml). Enzymatic 
modification of the antibiotic or single-step point mutations in the ribosome can 
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contribute to high-level streptomycin resistance in enterococci (Hollenbeck & Rice, 
2012). The ant(6´)-Ia that encodes for an adenylyl transferase is one of the well-known 
resistance determinants that can inactivate streptomycin. The ant(6´)-Ia gene is often 
found as part of a multi-resistance gene cassette ant(6 ´)-sat4-aph(3´) which confers 
resistance to streptomycin, streptothricin, and kanamycin. This gene cluster is encoded 
on Tn5405 and other related transposons that are widely found in Staphylococci and 
Enterococci (Derbise et al., 1997). Other AMEs that contribute to acquired 
aminoglycosides to enterococci include those that are encoded by aph(3´)-IIIa and 
ant(4´´)-Ia, which confer resistance to kanamycin, tobramycin, amikacin, and neomycin.  
Due to the growing problem and clonal spread of VREfm, new drugs such as linezolid, 
daptomycin, and tigecycline have been increasingly used to treat infections caused by 
VREfm. However, resistance has also been observed in these antibiotics (Edelsberg et al., 
2014; Tsai et al., 2012). With very few effective therapeutic options left to treat VREfm, 
development of newer drugs targeting different structures in the E. faecium cell, as well 
as strict infection control measures are utmost important to combat this pathogen.  
 
2.7 Biofilm formation by E. faecium  
Biofilm formation is an important virulence feature responsible for the pathogenesis 
of enterococci. Several difficult-to-treat enterococcal diseases were often biofilm-
mediated, including those associated with indwelling medical devices and urinary 
catheters, as well as endocarditis (Donlan et al., 2002). Several studies have also reported 
the association of biofilm formation to enterococci isolated from clinical settings 
(Baldassarri et al., 2001; Mohamed et al., 2004; Toledo-arana et al., 2001). Although 
clinical E. faecalis isolates are more frequently found to form biofilm, E. faecium biofilm 
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formation by clinical isolates is still relatively high compared to those isolated from other 
sources (Almohamad et al., 2014).  
Multiple biofilm-associated genes have been identified, mostly originated from E. 
faecalis. In E. faecium, these genes are mostly associated with adhesins or pili which are 
involved in the initial attachment step in biofilm formation. The enterococcal surface 
protein (Esp) is among the first cell-wall associated proteins that are shown to involve in 
biofilm formation in E. faecium (Heikens et al., 2007). The levels of esp expression on 
cell surface have been reported to affect initial attachment and biofilm formation (van 
Wamel et al., 2007), thereby explaining the conflicting observations that some esp 
positive isolates are unable to form biofilm (Dupre` et al., 2003). Further genetic analysis 
identifies a gene encoding an AraC-type transcriptional regulator, known as ebrB 
(enterococcal biofilm regulator B), which is found upstream of the esp gene. Deletion of 
ebrB resulted in reduced expression of esp, as well as reduced biofilm formation (Top et 
al., 2013). These results indicate that ebrB is involved in regulation of esp expression and 
is implicated in biofilm formation in E. faecium.  
Microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) 
are a group of surface proteins that plays an important role in host-pathogen adherence, 
as well as binding of bacteria to abiotic surfaces coated with host-derived extracellular 
matrix components. Two E. faecium MSCRAMMs that are involved in biofilm formation 
are Acm and SgrA. Acm, a cell wall-anchored collagen adhesin which binds to collagen 
type I and type IV is highly prevalent in E. faecium clinical isolates (Nallapareddy et al., 
2008a). Although this adhesin is also found in non-clinical isolates, the gene encoded for 
this protein (acm) shows an insertion element disruption, rendering the encoded protein 
non-functional (Nallapareddy et al., 2008a). An acm deletion mutant has been shown to 
reduce biofilm formation in E. faecium. Furthermore, this acm mutant is also less virulent 
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in a rat endocarditis model, indicating the contribution of acm to E. faecium pathogenesis 
(Nallapareddy et al., 2008). The surface adhesin SgrA, on the other hand, binds to 
extracellular matrix molecules nidogen 1 and nidogen 2. Although SgrA does not mediate 
binding of E. faecium to biotic surfaces such as human bladder and intestinal epithelial 
cells, its contribution to biofilm formation on polystyrene surface was demonstrated 
(Hendrickx et al., 2009). 
Another group of surface expressed proteins that contributes to E. faecium biofilm 
formation is pili. Two pilus-like structures, PilA and PilB, are frequently found in clinical 
E. faecium isolates, including those isolated from endocarditis patients (Hendrickx et al., 
2010, 2008). The pilA gene is part of the pilA (fms21)-fms20 gene cluster which is 
encoded on a large transferable plasmid (Kim et al., 2010). On the other hand, pilB, also 
known as ebpC or fms9, is part of the ebpABCfm cluster and encodes for a major pilus 
PilB. Deletion of ebpABCfm eliminates cell surface expression of PilB-containing pili and 
reduces biofilm formation. Additionally, the deletion mutant displays reduced 
colonization in a murine UTI model, signifying the role of ebpABCfm in the pathogenesis 
of E. faecium (Sillanpää et al., 2011).  
Other than factors involving in initial attachment, several proteins that are associated 
with maturation of biofilm are also identified in E. faecium. These include a major 
autolysin, AltEfm, and a secreted protein, SagA. AltEfm involves in the release of 
extracellular DNA (eDNA), which is one of the important components of extracellular 
polymeric substances. The importance of AltEfm in biofilm formation has been 
demonstrated through insertion disruption of the autolysin gene (Paganelli et al., 2013). 
Besides eDNA, secreted proteins are also an important component in the biofilm matrix. 
The secreted protein SagA presents abundantly in the biofilm of E. faecium strains 
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(Paganelli et al., 2015). Proteolytic degradation of SagA has been shown to markedly 
reduce biofilm formation of clinical E. faecium strains (Paganelli et al., 2015).  
 
2.8 Transcriptome study 
Transcriptome is the total mRNA in a cell that represents genes that are actively 
expressed at a specific growing stage or physiological condition (Wang et al., 2009). 
Transcriptomic aims to elucidate the functional elements of a genome; to determine the 
transcriptional structure of genes; and to quantify gene expression levels under different 
conditions (Wang et al., 2009).  Understanding the transcriptome is, therefore, important 
to unravel the underlying molecular mechanisms of bacterial development and 
pathogenesis.  
Microarray technology has been widely used in the transcriptomic analyses of different 
microorganisms. However, this hybridization-based method has several limitations, 
including a limited dynamic range of transcript detection due to problems with 
background noise and saturation of signals, dependency on the existing knowledge of 
genomes or transcripts, and complex normalization methods in comparing different 
experiments (Hinton et al., 2004; Wang et al., 2009). With the advent of next generation 
sequencing technologies, a more recent technology for transcriptome profiling termed 
RNA-seq (RNA sequencing) has been developed. In contrast to the microarray, 
transcriptomic studies using RNA-seq are not limited to previously known genes as this 
method directly determines the cDNA sequences (Wang et al., 2009). Moreover, RNA-
seq provides better resolution and higher reproducibility compared to microarray (Wang 
et al., 2009). With all these advantages, RNA-seq technology has provided a large amount 
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of data which refined our understanding in the gene expression profile of an organism 
under different treatments or environmental stresses.  
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CHAPTER 3: METHODOLOGY 
3.1 Clinical data collection and patients’ background  
Clinical data including the patients’ ward, samples source, samples isolation date, 
antibiotic treatments and surgical procedures of the studied patients was collected. Ethical 
approval had been obtained from the University of Malaya Research Ethics Committee 
(UMREC) with ethical approval number 20159-1661. 
Patient X was admitted into cardiology ward in 24th October 2010. Subsequently after 
the isolation of first VRE (VRE2) from this patient, VRE infection cases were frequently 
reported in the hospital. Patient Y was admitted into neuro-ICU ward due to basal ganglia 
bleed approximately three months (21st January 2011) after patient X was admitted. 
Microbiological investigation revealed that patient Y was infected by multiple pathogens, 
including multidrug-resistant Acinetobacter baumannii, methicillin-resistant 
Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa. VREr5 was isolated 
from patient Y after one month of treatment with vancomycin. Following this, another 
two strains, VREr6 and VREr7, were isolated from the same patient who was undergoing 
an antibiotic treatment with meropenem, colistin, ceftazidime, and linezolid. After the 
linezolid treatment, VRE had not been isolated from patient Y. To note, patient Y 
underwent several surgical procedures such as intracranial pressure monitoring and 
external ventricular drain insertions (EVD) during hospitalization. These procedures may 
serve as the route of bacterial transmission although this association is unclear. 
Eventually, patient Y died of sepsis due to infective endocarditis and pneumonia. 
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3.2 Whole genome sequencing  
3.2.1 Bacterial strains  
Four clinical strains of vancomycin-resistant E. faecium (VRE2, VREr5, VREr6, 
VREr7) were collected in the year 2011 from University Malaya Medical Centre 
(UMMC), Kuala Lumpur. These strains were selected based on previous PFGE results, 
which were reconfirmed in this study. The strains were isolated and validated through 
PCR-amplification and sequencing of the 16S rRNA at the clinical microbiology 
laboratory. VRE2 was isolated from patient X and was the first VREfm isolated in the 
studied period. VREr5, VREr6, and VREr7 were isolated from the cerebrospinal fluid 
(CSF), blood, and urine of patient Y, respectively. These three strains were isolated at 
one-week interval, with VREr5 being the first isolate, followed by VREr6 and VREr7. A 
single colony of each strain was then cultured into Brain Heart Infusion broth (Oxoid 
Ltd., Basingstoke, UK) and incubated at 37°C for 24 hr. The culture was stored at -80°C 
in 50% glycerol until further experiments.  
 
3.2.2 Pulsed-field gel electrophoresis (PFGE) 
PFGE was performed as previously described (Turabelidze et al., 2000), with slight 
modifications. Briefly, the bacteria were first lysed in a combination of lysozyme 
(100mg/ml) and mutanolysin (10kU/ml) at 37°C for four hours. Chromosomal DNA was 
then prepared in agarose gel block and digested with restriction enzyme SmaI (Promega, 
Madison, WI, USA) at room temperature. The restriction fragments were separated by 
electrophoresis in 0.5 x TBE buffer for 20 hr at 14°C in a CHEF Mapper system (Bio-
Rad, CA, USA) using pulsed times of 3.5-25 s and 1-5 s. XbaI-digested Salmonella 
enterica ser. Braenderup H9812 was used as a DNA size marker. The PFGE data were 
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analyzed using BioNumerics version 6.0 software (Applied Maths, Kortrijk, Belgium). 
The quantitative differences in the banding patterns were defined by the Dice coefficient. 
Cluster analysis was determined based on the unweighted pair group method with 
averages (UPGMA), using a position tolerance 1.5%. 
 
3.2.3 DNA extraction 
Genomic DNA of the four VREfm strains were extracted using the Wizard Genomic 
DNA Purification Kit (Promega, Madison, Wisconsin, United States). Briefly, 1 ml of the 
bacterial culture was harvested by centrifugation for 2 min at 14,000 rpm. To weaken the 
cell wall of gram-positive bacteria, the cell pellet formed was re-suspended in 480 µl of 
EDTA (50mM), after which 120 µl of lysozyme (10mg/ml) was added. The sample was 
incubated at 37°C for one hour, followed by centrifugation for 2 min at 14,000 rpm. The 
supernatant was removed and the cell pellet was re-suspended in 600 µl of lysis solution. 
The sample was further incubated at 80°C for 5 min. Following this, 3 µl of RNase 
solution was added to the re-suspended pellet, mixed, and incubated at 37°C for 15 to 60 
min. After incubation, 200 µl of protein precipitation solution was added and vortexed to 
mix. The sample was incubated on ice for 5 min prior to centrifugation for 3 min at 14,000 
rpm. The resultant supernatant was transferred to a clean microcentrifuge tube containing 
600 µl of room temperature isopropanol and then followed by centrifugation at 14,000 
rpm for 2 min to recover the precipitated DNA. The supernatant was discarded and 600 
µl of room temperature 70% ethanol was added to clean the DNA pellet. The solution 
was centrifuged for another 2 min at 14,000 rpm. The ethanol was carefully aspirated and 
the pellet was air-dried for 10 to 15 min. Finally, the dried DNA pellet was re-suspended 
in 100 µl of sterile distilled water. Extracted DNA was quantified using the 
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spectrophotometer at OD260 and the purity was determined by OD260/OD280 ratio. The 
extracted DNA was stored at -20°C for long term storage.  
 
3.2.4 Genome sequencing, assembly, and annotation 
Whole genome sequencing of the VRE2, VREr5, VREr6, and VREr7 was carried out 
by a commercial vendor using the Illumina Miseq platform, version 2.0 with reads 
coverage ranged from 78x to 108x. The genome sequences were then assembled using 
CLC Genomic Workbench version 5.1 (CLC Bio, Aarhus, Denmark). Open reading 
frame (ORF) prediction was performed using Prodigal (Hyatt et al., 2010). Functional 
annotated of the genomes was performed using RAST (Rapid Annotation using 
Subsystem Technology) (Aziz et al., 2008) and Blast2GO (Conesa et al., 2005).   
 
3.2.5 Genome analyses and comparative studies 
The sequence types of the four sequenced strains were determined in silico using the 
PubMLST database (http://pubmlst.org/). Genomes alignment and comparison were 
performed using Mauve 2.3.1 using E. faecium Aus0085 as the reference (Darling et al., 
2004). The circular genomic map was constructed using BLAST ring image generator 
(BRIG) (Alikhan et al., 2011). Insertion sequence (IS) elements, prophages, and clustered 
regularly interspaced short palindromic repeats (CRISPR) were identified using IS Finder 
(Siguier et al., 2006), PHAST (Zhou et al., 2011), and CRISPRfinder (Grissa et al., 2008), 
respectively.  
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3.2.6 Phylogenomic analysis 
For phylogenomic analysis, sixteen draft genomes of clinical E. faecium from ten 
different countries (Austria, United States of America, Netherlands, France, China, 
Africa, Portugal, United Kingdom, Israel, and Denmark) with 11 different STs (ST 203, 
17, 78, 117, 18, 210, 27, 26, 414, 160, and 64) were retrieved from NCBI database and 
compared with our four sequenced draft genomes. The names and respective Genbank 
accession numbers of the sixteen strains are as follows: Aus0085 (CP006620.1), Aus0004 
(CP003351.1), TX16 (CP003683.1), E1133 (AHWR00000000.1), E155 
(AUWX00000000.1), E1904 (AHXQ00000000.1), E0120 (AHWI00000000.1), E2560 
(AHYI00000000.1), E1185 (AHWS00000000.1), E161 (JXZA00000000.1), LCT-EF128 
(AJUP00000000.1), E1731 (AHXO00000000.1), E6045 (AHYL00000000.1), E1392 
(AHWV01000046), E0333 (AHWL00000000.1), VRE84 (AIVF00000000.1). Genome 
sequences were submitted to the Reference Sequence Alignment-based Phylogenic 
Builder (RealPhy) (Bertels et al., 2014) for the identification of sites that are relevant for 
the phylogenomic study. E. faecium Aus0085 was chosen as the reference genome as this 
strain shares similar features with our Malaysian strains and has the same sequence type 
(ST 203) as two of these strains. Aus0085 is a clinical VRE isolate with known complete 
genome sequence (Lam et al., 2013). The generated multiple genome sequence 
alignments were used to construct an approximately-maximum-likelihood tree using 
FastTreeMP as previously described (Price et al., 2010; Yap et al., 2014).   
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3.2.7 GenBank accession numbers 
The genome sequences of E. faecium strains VRE2, VREr5, VREr6, and VREr7 were 
deposited in GenBank under accession number LTAA00000000, LTBJ00000000, 
LTDQ00000000, and LSZZ00000000, respectively.  
 
3.3 Virulence factors  
3.3.1 Virulence genes identification 
The Virulence Factors of Pathogenic Bacteria database (Chen et al., 2005) was used 
to identified virulence profile of the studied strains. Only results with more than 60% 
coverage and 60% sequence identity were considered positive for the analysis. Selected 
virulence genes were further verified by PCR amplification and DNA sequencing of the 
amplicons.  
 
3.3.2 Biofilm assay 
To study the biofilm forming ability of the selected strains, crystal violet assay was 
performed as described by Baldassarri et al. (2001) with slight modifications. Briefly, 
overnight cultures were prepared using tryptic soy broth (TSB) (Oxoid Ltd., Basingstoke, 
UK) containing 6 μg/ml vancomycin. The overnight cultures were diluted 1: 100 and 200 
μl was inoculated into 96-well polystyrene flat-bottom microtiter plate. The inoculated 
plate was incubated at 37°C for 48 hr. After incubation, the plate was tapped vigorously 
followed by two times washing with 1x phosphate buffered saline (PBS) to remove 
unbound cells. The bounded cells were fixed at 60°C for 45 min and subsequently stained 
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with 200 µl crystal violet (0.1%) for 10 min. The plates were then washed with PBS thrice 
and dried before adding 200 µl 80:20 ethanol-acetone. The absorbance of the eluted stain 
was measured at 590nm wavelength. The true OD readings of each strain were acquired 
after deducting the negative control, which contained only the growth medium.  
The biofilm forming ability of the studied strains was scored as previously described  
(Chelvam et al., 2014; Stepanović et al., 2000). Briefly, the cut-off OD (ODc) was defined 
as three standard deviations above of the mean OD of the negative control. The biofilm 
forming ability of each strain was scored as follow: OD ≤ ODc = non-biofilm producer, 
ODc < OD ≤ (2x ODc) = weak-biofilm producer, (2x ODc) < OD ≤ (4x ODc) = moderate-
biofilm producer, OD > (4x ODc) = strong-biofilm producer. The experiment was 
performed in triplicate and repeated three times for reproducibility.  
 
3.3.3 Confocal Laser Screen Microscopy (CLSM) 
To confirm the results obtained from crystal violet assay, CLSM was performed. 
Biofilm was grown in an eight-well chamber slide at 37°C for 48 hr. Visualization of 
biofilm was performed as previously described (Jurcisek et al., 2011). Briefly, planktonic 
cells were removed by gentle pipetting, and the biofilm was washed with sterile PBS 
twice. The biofilm was stained with 200 μl of BacLight Live/Dead Kit (Invitrogen Ltd., 
Paisley, UK) for 15 min at dark and subsequently fixed with 200 μl of neutral buffer 
formalin (NBF) for 30 min. The stained biofilm was later washed with sterile saline twice. 
An appropriate amount of sterile saline was added to the slide before applying the 
coverslip to keep the biofilm hydrated during imaging. Confocal images were collected 
using a Leica TCS SP5 microscope. The images were viewed by using the LAS AF Lite 
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software (Leica). The image stacks were acquired using ImageJ software (Fiji, ImageJ, 
Wayne Rasband National Institutes of Health).  
 
3.3.4 Determination of the plasmid origin of E. faecalis bee homolog  
To determine the location of the E. faecalis bee locus identified in VREr5, both total 
and plasmid DNA were extracted. Total DNA was extracted by cell boiling method. 
Briefly, one single colony was suspended in 100 μl of distilled water and boiled for 5 min 
at 99°C. The bacterial suspension was then immediately cooled on ice for 10 min followed 
by centrifugation for 5 min at 13,400 rpm. The supernatant was transferred to a new 500 
μl Eppendorf tube and stored at -20°C.  
Plasmid DNA was extracted using QIAprep spin miniprep kit (Qiagen, Hilden, 
Germany). 5 ml of overnight culture was centrifuged at 6800xg at 25°C for 3 min. The 
pelleted bacterial cell was re-suspended in 250µl Buffer P1 and transferred to a clean 2 
ml microcentrifuge tube. A total of 250 µl Buffer P2 was added and the tube was inverted 
four to six times to mix the solution. Following this, 350 µl Buffer N3 was added and the 
mixture was mixed immediately by inverting the tube four to six times. After this, the 
mixture was centrifuged at 13,000 rpm for 10 min and the resultant supernatant was 
transferred to a clean QIAprep Spin Column. The supernatant was centrifuged for 60 s 
and the flow-through was discarded. To the QIAprep Spin Column, 500 µl Buffer PB was 
added, followed by centrifugation at 13,000 rpm for 60 s. After removing the flow-
through, the QIAprep Spin Column was washed by adding 750 µl Buffer PE and 
centrifuged again for 60 s. Residual washing buffer was removed by centrifugation for 
another 60 s, after removing the flow-through. The QIAprep Spin Column was then 
transferred to a new 1.5 ml microcentrifuge tube. To elute the plasmid DNA, 50 µl of 
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deionized water was added directly to the membrane of the QIAprep Spin Column, let 
stand for 1 min, and centrifuge for 60 s. The extracted plasmid DNA was stored at -20°C.  
Polymerase Chain Reaction (PCR) was performed using novel primers designed to 
detect the bee-1 and bee-2 genes and primers adopted from Tendolkar et al. (2006) for 
detection of bee-3 gene  (P101D12-1, Bee-12) (Appendix 4). A 5 μl aliquot of each PCR 
product was electrophoresed on a 1.5% agarose gel for 30 min at 100V. The gel was 
stained with GelRedTM nucleic acid gel stain (Biotium) for 15 min. The gel image was 
visualized with Gel documentary system (Bio-rad, Hercules, CA).  
 
3.4 Antibiotic resistance  
3.4.1 Antibiotic susceptibility tests (AST) 
The Kirby-Bauer disc diffusion method was used to test the susceptibility of the E. 
faecium strains to the following ten antibiotics (Oxoid Ltd., Basingstoke, UK): 
vancomycin (30 μg), gentamicin (120 μg), streptomycin (10 μg), kanamycin (30 μg), 
ampicillin (10 μg), erythromycin (15 μg), clindamycin (2 μg), tetracycline (30 μg), 
teicoplanin (30 μg), and linezolid (30 μg). The antibiotic susceptibility test was carried 
out on Mueller-Hinton (Brcton Dickson, NJ, USA) Agar swabbed with 0.5 McFarland 
standard suspension of E. faecium and incubated at 37°C for 18 hours. For vancomycin, 
the plate was incubated for 24 hours. Guidelines from the Clinical and Laboratory 
Standards Institute (CLSI) (Clinical and Laboratory Standards Institute, 2016) were used 
to interpret the diameters of the inhibition zones produced.  
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3.4.2 MIC determination for vancomycin, teicoplanin, and gentamicin 
The minimal inhibitory concentration (MIC) values of vancomycin, teicoplanin, and 
gentamicin were determined using E-test strips (BioMérieux, Marcy-I’Étoile, France). E. 
faecium cultures were adjusted to 0.5 McFarland standard and swabbed uniformly on 
Mueller-Hinton agar (Becton Dickson, NJ, USA). E-test strips were applied to the surface 
of the agar and the inoculated plates were incubated at 37°C for 16 to 20 hr. The MIC 
values were recorded and interpreted according to the guidelines from the Clinical and 
Laboratory Standards Institute (CLSI) (Clinical and Laboratory Standards Institute, 
2016).  
 
3.4.3 Identification and confirmation of vancomycin-resistant subtype 
The vancomycin-resistant subtype (vanA) of the selected strains were confirmed by 
PCR using specific primers (Kariyama et al., 2000) and condition as shown in Appendix 
4. Following PCR amplification, 5 μl of each amplicon was loaded into a 1.5% (w/v) 
agarose gel and electrophoresis was performed at 100V for 30 min. The gel was stained 
with GelRedTM nucleic acid gel stain (Biotium) for 15 min. The gel image was captured 
and analyzed with Gel documentary system (Bio-rad, Hercules, CA) 
PCR products with the desired size were purified using Wizard SV Gel and PCR 
Clean-up system (Promega, Madison, Wisconsin, United States). An equal volume of 
membrane binding solution was added to the PCR amplification product and mixed 
thoroughly. The solution was transferred to a Mini-column and incubated at room 
temperature for 1 min. The sample was centrifuged at 16,000x g for 1 min and the flow-
through was discarded. Following this, 700 µl of membrane wash solution was added and 
the sample was centrifuged for 1 min at 16,000x g. After discarding the flow-through, 
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another 500 µl of membrane wash solution was added followed by centrifugation for 5 
min. The empty Mini-column was further centrifuged for 1 min to remove residual 
ethanol. Purified DNA was eluted by adding 50 µl of sterile distilled water.  
The purified DNA was sent to a laboratory (First Base Sdn. Bhd., Seri Kembangan, 
Malaysia) for sequencing together with the forward and reverse PCR primers. DNA 
sequences obtained were trimmed using Mega 6 (downloadable from 
http://www.megasoftware.net/) and analyzed with standard nucleotide-nucleotide 
BLAST at the National Center for Biotechnology Information website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
3.4.4 Antibiotic resistance genes determination 
To identify antibiotic resistance genes, the nucleotide sequences of the four sequenced 
strains were submitted to the Antibiotic Resistance Gene Database (ARDB) (Liu and Pop, 
2009). A resistance profile with corresponding resistant genes was generated for each 
strain. The nucleotide sequences were also submitted to ResFinder 2.1 server (Zankari et 
al., 2012) to identify acquired antimicrobial resistance genes in the genome of each strain.  
 
3.4.5 Tn1546 structural analysis  
The molecular structures of the Tn1546-like elements were analyzed using published 
PCR primers (Huh et al., 2004; Simjee et al., 2002). 5235.F and 7035.R (Simjee et al., 
2002) were used to fill the gap between the two contigs carrying the van genes of the 
Tn1546-like elements. Primer ISV650F and ISV132R (Huh et al., 2004) were used to 
detect the presence of IS1216V. To determine the DNA sequences of the right end of the 
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truncated Tn1546-like elements, primer 4511R was used with combination of the 
IS1216V-specific primers (ISV650F, ISV132R). All amplicons were sequenced 
commercially (First Base Sdn. Bhd., Seri Kembangan, Malaysia). The DNA sequences 
were analyzed using CodonCode Aligner (CodonCode Corporation, Dedham, MA) to 
obtain the exact structure of the Tn1546-like elements.  
 
3.5 Transcriptomic analyses of E. faecium biofilm  
3.5.1 Confirmation of biofilm developmental stage using CLSM 
VREr5, the only biofilm former among the four studied strains, were selected for the 
transcriptomic study. In order to study the change in gene expression levels during the 
transition from planktonic to biofilm cells, VREr5 was allowed to form biofilm for a 
period of 24 hours. To verify that VREr5 was in the initial stage of biofilm development, 
CLSM was performed using the protocol previously described in section 3.4.3.  
 
3.5.2 Total RNA extraction  
Total RNA of both planktonic- and biofilm-state cells was extracted using Wizard SV 
Total RNA Extraction System (Promega, Madison, Wisconsin, United States) with slight 
modifications.  
For planktonic-state cells, overnight cultures in TSB (Oxoid Ltd., Basingstoke, UK) 
were diluted 1:50 and allowed to grow until the OD600 of 0.8. Then, 1 ml of the culture 
was harvested at 4°C by centrifugation at 14,000x g for 2 min. For biofilm-state cells, 
biofilm was first allowed to grow in a 24-well microtiter plate for 24 hours and unbound 
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cells were removed by washing with PBS. The attached cells were scraped out using the 
pipette tip and re-suspended in PBS. The re-suspended cells were harvested at 4°C by 
centrifuging at 14000x g for 2 min. To the resulting pellet harvested from both biofilm 
and planktonic cells, 60 μl each of freshly prepared lysozyme (10mg/ml) and mutanolysin 
(10kU/ml) was added and vortexed. The re-suspended pellet was incubated at room 
temperature for 15 min. After incubation, 75 μl of RNA lysis buffer was added, followed 
by 350 μl of RNA dilution buffer, and the mixture was mixed by inversion. The clear 
lysate solution was then mixed with 200 μl of 95% ethanol, transferred to the clean Spin 
Column assembly, and centrifuged for 60 s at 14,000x g. After discarding the flow-
through, 600 μl of the RNA wash solution was added to the spin column, followed by 
centrifugation at 14,000x g for 60 s. The flow through was discarded. A total of 50 μl 
DNase incubation mix was added directly to the membrane of the spin column and 
incubated at room temperature for 15 min. The DNase incubation mix was prepared 
according to the Table 3.1: 
Table 3.1: DNase incubation mix setup 
Solution Volume per prep 
Yellow Core Buffer 40 μl 
MnCl2 5 μl 
DNase I 5 μl 
 
 After incubation, 200 μl of DNase stop solution was added to the column and 
centrifuged for one minute at 14,000 x g. Following this, 600 μl of RNA wash solution 
was added and the centrifugation step was repeated. The flow through was discarded. The 
spin column was centrifuged for two minutes at high speed after the addition of 250 μl of 
RNA wash solution. The spin basket was transferred to a clean 1.5ml microcentrifuge 
tube and 100 μl of nuclease-free water was added directly to the membrane of the column. 
The RNA was eluted by centrifugation at 14,000 x g for 60 s.  
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The extracted RNA was quantified using NanoDrop (IMPLEN, Germany). To access 
the RNA integrity, 1µl of RNA sample was mixed with 4 μl of 1x TE and electrophoresis 
was performed on 1% agarose gel. The extracted RNA was stored at -80°C until further 
use.  
 
3.5.3 RNA-seq and data processing 
The quality of RNA samples was re-checked using Qubit 2.0 (Invitrogen, California, 
USA) with the Qubit RNA HS assay (Life Technologies, California, USA) and Agilent 
2100 bioanalyzer (Agilent Technologies, Santa Clara, California, United States) before 
sending for sequencing. RNA-seq was performed by a commercial vendor on the Illumina 
HiSeq platform. The quality of the sequenced reads was checked using Novogene in-
house quality control software. The low-quality reads, which 1) contained adaptor 
contamination, 2) contained N> 10%, and 3) with low-quality base (>50% of the total 
base has quality score ≤ 5) were removed. de novo assembly was performed using CLC 
Genomic Workbench software (Version 7.5.1, CLC Bio, Denmark). Following this, 
coding sequences (CDS) were identified using TransDecoder and were annotated by 
performing BLASTp and BLASTx against the NCBI nr protein database and Swiss-Prot 
database with an E-Value cut-off of 1e-5. Functional annotation was performed by 
Blast2GO program (Conesa et al., 2005) to obtain the GO annotation and KEGG 
pathways. The COG assignment was carried out using the eggNOG mapper (Huerta-
Cepas et al., 2016). 
Reads quantification was carried out by mapping back the raw reads to the generated 
transcripts using the CLC Genomic Workbench software. Differentially expressed genes 
were determined using the Empirical analysis of DGE algorithm of the same software. 
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Genes with a False Discovery Rate (FDR)-corrected p-value < 0.001 and an absolute 
value of log2 fold change (log FC) > 2 were identified as being differentially expressed. 
A p-value < 0.05 was used as a cut-off for determining significantly up- and down-
regulated genes.  
 
3.5.4 Quantitative Real-time PCR for validation of RNA-seq results 
Extracted RNA using protocol described in section 3.5.2 was subjected to reverse 
transcription using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, California, USA).  
The master mix for reverse transcription was prepared on ice as in Table 3.2. The PCR 
running condition for the reverse transcription is listed in Table 3.3. 
 
Table 3.2: Master mix setup for reverse transcription 
Component Volume per reaction 
Nuclease-free water 4.2 μl 
10x RT buffer 2.0 μl 
10x RT primer 2.0 μl 
25x dNTP mix (100mM) 0.8 μl 
Reverse transcriptase 1.0 μl 
Total RNA template 10.0 μl 
 
Table 3.3: PCR running condition for reverse transcription 
 Temperature (°C) Time (min) 
Step 1 25 10 
Step 2 37 120 
Step 3 85 5 
Step 4 4 ∞ 
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Real-time PCR was performed using qPCRBIO SyGreen Blue Mix (PCR Biosystems, 
London, UK). To determine the efficiency and specificity of the assay, standard curve 
with five dilution points and melt curve were performed for each of the selected up-
regulated (ebpA, tetS, repR) and down-regulated (arcA, fsrB, bee-2) genes as well as 
housekeeping gene (ddl). The reaction master mix was setup according to Table 3.4. The 
reaction was run on a ViiA 7 Real-Time PCR system (Applied Biosystem, California, 
USA). Real-time cycling condition for the reactions is listed in Table 3.5.  Melt curve 
running condition is listed in Table 3.6. During the experiment, melting curve profile for 
each amplification reaction and the relevant Ct value was automatically generated, using 
the software provided with the system. The expression values of the target genes in 
biofilm cells were quantified by the relative standard curve method, using ddl as the 
endogenous control and planktonic sample as reference.  
 
Table 3.4: Master mix setup for real-time PCR 
Component Volume (µl) per 
reaction 
Final concentration 
2 x qPCRBIO SyGreen Blue 
Mix 
10 1 x 
Forward primer (10µM) 0.8 400nM 
Reverse primer (10µM) 0.8 400nM 
Template cDNA (100 - 
0.16ng) 
1 Variable 
PCR grade dH2O 7.4 - 
Total reaction volume 20 - 
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Table 3.5: Real-time PCR cycling condition 
 Polymerase 
activation 
PCR (40 cycles) 
 Hold Denaturation Annealing/Extension 
Temperature (°C) 95 95 60 
Time 2 min 5s 20s 
 
 
Table 3.6: Melt curve running condition 
 Temperature (°C) Time 
Step 1 95 15 s 
Step 2 60 1 min 
Step 3 (Dissociation) 95 15 s 
 
 
3.5.5 Raw transcriptome data deposition  
The cleaned raw sequences were deposited in the NCBI’s Sequence Read Archive 
(SRA) under the experiment accession numbers SRX2783031 to SRX2783036.   
 
 
 
 
41 
    
CHAPTER 4: RESULTS  
4.1 Whole genome sequencing   
4.1.1 Pulsotypes of VREfm 
PFGE subtyping of the four clinical strains revealed three pulsotypes comprising 16-
27 restriction fragments (Figure 4.1). Cluster analysis at 90% similarity yielded two 
clusters. VREr6 and VREr7, which were isolated from the same patient (patient Y), were 
identical to each other (Cluster II). Interestingly, VREr5, which was also isolated from 
patient Y, was grouped into a different PFGE cluster (cluster I). Instead, VREr5 showed 
similar PFGE profile as VRE2 which was isolated from patient X, differing by only two 
bands. 
 
 
Figure 4.1: Dendrogram showing the cluster analysis of four VREfm strains based on 
PFGE patterns of the SmaI-digested chromosomal DNA. The dendrogram was 
constructed using the Dice coefficient and UPGMA clustering parameters at 1.5% 
position tolerance. The strain code, source, host, and cluster are indicated. The dotted 
vertical line indicates 90% similarity level. 
 
 
 
 
42 
    
4.1.2 Genome features 
Whole genome sequence analysis indicated that the estimated genome sizes of the four 
VREfm strains ranged from 2.8 Mbp to 3.0 Mbp. All these strains had guanine-cytosine 
(GC) contents of approximately 38%. The numbers of predicted protein coding sequences 
(CDS) of the four genomes ranged 2853 to 3057. Both VRE2 and VREr5 harbored 55 
tRNA genes whereas VREr6 and VREr7 harbored 58 tRNA genes. The general genome 
features of these four strains are summarized in Table 4.1.  
 
Table 4.1: General genome features of VREfm strain VRE2, VREr5, VREr6, and 
VREr7. 
 
 
4.1.3 Multilocus sequence typing (MLST) 
The sequence types (STs) of the four VREfm strains were determined by the existing 
E. faecium MLST scheme which uses the following seven housekeeping genes: atpA, ddl, 
ghd, purK, gyd, pstS, and adk. VRE2 and VREr5 were assigned to ST80 (9-1-1-1-12-1-
1) whereas VREr6 and VREr7 were assigned to ST203 (15-1-1-1-1-20-1). Both these STs 
are grouped under clonal complex 17 (CC17), a specific lineage associated with 
nosocomial E. faecium strains (Top et al., 2008).  
 
 VRE2 VREr5 VREr6 VREr7 
Genome size (bp) 2,862,609 2,898,367 3,014,993 3,021,201 
GC% 37.85 37.8 37.61 37.6 
Number of CDS 2,853 2,906 3,049 3,057 
Number of tRNA 55 55 58 58 
Number of rRNA 3 3 3 3 
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4.1.4 Comparative genomics  
The genomes of the four Malaysian strains were compared to that of the reference 
strain E. faecium Aus0085 (GenBank accession number CP006620.1), one of the 13 E. 
faecium complete genomes known up to date. Aus0085 was chosen as the reference strain 
as it shares similar features with the four local VREfm strains. This clinical VRE strain 
was from similar geographical region as the four local strains, and was isolated from 
blood sample of a bacteremia patient (Lam et al., 2013). Moreover, this strain also has 
same ST as two of our strains (VREr6, VREr7).  
Genomic comparison revealed that a total of 2148 open reading frames (ORFs) were 
shared among all the genomes. This conserved ORFs accounted for approximately 71% 
of the total ORFs present in each of the studied strains, which was comparable to other 
study (Lam et al., 2012). At least four chromosomal regions spanning approximately 169 
kbp in Aus0085 showed low or no homology (<70%) with the four Malaysian strains, 
including a region carrying the vanB-containing Tn1549 transposon (Figure 4.2). VREr6 
and VREr7 shared higher similarity between each other and with the reference genome 
compared to VRE2 and VREr5, probably due to the same ST. Consistent with this result, 
higher number of shared genes were also observed between VREr6 and VREr7 when the 
four strains were compared among themselves (Figure 4.3). Similarly, VRE2 and VREr5 
also shared more genes as compared to the other two strains (Figure 4.3). Some of these 
shared genes were associated with additional fitness and survival advantage. These 
included a cluster of genes encoding inositol metabolism proteins found only in VRE2 
and VREr5, and a gene encoding lactococcin 972 (Lcn972) found only in VREr6 and 
VREr7. Moreover, each of the four strains also carried different number of strain-specific 
genes, ranging from 16 to 57. Most of these strain-specific genes encoded for hypothetical 
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proteins and mobile element proteins, which might play a crucial role in determining 
distinct virulence features of each strain. 
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Figure 4.2: Circular genomic map and genome comparison of Aus0085, VRE2, VREr5, VREr6, and VREr7. The inner ring shows coordinate in scale 
and the total genome size of the reference sequence, Aus0085. The black histogram bar represents GC content whereas the purple-green histogram 
bar represents GC skew. Colored arches representing orthologous regions of each genome in respect to Aus0085 (purple arch) and are shown in the 
following order (inside to outside): Aus0085, VRE2, VREr5, VREr6, VREr7. The outermost arch (black) represents the location of Tn1546, 
phiEnfa005, phiEnfa006, and inositol catabolism genes relative to Aus0085.   
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Figure 4.3: Venn diagram showing the distribution and number of core, dispensable and 
strain-specific genes of the Malaysian VREfm strains. Each circle is labelled with the name 
of its representative strain. A total of 2494 genes are shared among the analyzed strains. 
The number of strain-specific genes are 16, 44, 46, and 57 for VRE2, VREr6, VREr7, 
and VREr5, respectively. 
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4.1.5 Phylogenomic relationship of selected E. faecium strains 
To better understand the relationship among the four Malaysian strains and other 
global strains, phylogenomic analysis was carried out using the core genome alignments 
of the four Malaysian strains in comparison with other 16 E. faecium strains from ten 
different countries. E. faecium Aus0085 was used as a reference for the analysis. Based 
on the phylogenomic analysis (Figure 4.4), VREr6 and VREr7 were closely related, 
which is expected as both were isolated from the same host (patient Y). However, VREr5, 
which was also derived from patient Y, was more closely related to VRE2 isolated from 
a different patient (patient X). The phylogenomic tree also showed that VREr6 and 
VREr7 were closely related to strain E161 isolated from China. Notably, these two strains 
were also more closely related to the reference Aus0085 compared to VRE2 and VREr5. 
Additionally, a distinct separation of strains of ST17, ST18, and ST78 into two different 
clusters was also observed. Strains from ST17 (Aus0004, E155, EnGen0180) and ST18 
(DO, E1731) were clustered together and were closely related to the Malaysian strains, 
VRE2 and VREr5. Two strains from ST78 (E6045, E2560) formed another cluster which 
included VREr6 and VREr7.  
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Figure 4.4:  Phylogenomic tree inferred from approximately-maximum-likelihood 
method from aligned core genomes. Multiple genomes alignments are generated from 20 
global E. faecium strains using Aus0085 as a reference. The unrooted phylogenomic tree 
is inferred via approximately-maximum likelihood method using FastTreeMP (Price et 
al., 2010). Bootstrap support values are shown in each node. 
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4.1.6 Genomic plasticity 
The genomes of clinical E. faecium strains are known to plague with a high number of 
mobile genetic elements which contribute to their genome plasticity (Qin et al., 2012; van 
Schaik et al., 2010). Analyses of the four VREfm genomes revealed high genome dynamic 
among these strains contributed mainly by insertion sequences (IS), prophages, and 
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR).  
The number of IS elements found in the four genomes ranged from 43 to 55. These IS 
elements represent ten types of IS families, with members from the IS3 (IS1485, ISEfa8, 
ISEfa10, ISEnfa3) and ISL3 (IS1251, ISEfa11, IS1476, ISEfa5) families being the 
majority IS elements identified. Apart from that, IS16, which is ubiquitously found in 
clinical enterococcus strains (Werner et al., 2011), was also detected in the genomes of 
the four local strains.  
One prophage region was predicted in both VRE2 and VREr5 whereas two and three 
prophage regions were predicted in VREr6 and VREr7, respectively. The size of the 
predicted prophages ranged from 39.0 kb to 47.8 kb. Interestingly, the identified phages 
showed higher sequence similarity (99% to 100% nucleotide identity) with those from 
strains of the same sequence type. This included two regions in VREr6 and VREr7 which 
shared 93% to 95% sequence identity with phages phiEnfa005 and phiEnfa006 of 
Aus0085 (Figure 4.2). Majority of the ORFs (83.3% to 98.0%) in all the predicted 
prophage regions encoded for phage-specific proteins and hypothetical proteins. One 
prophage region of VREr7 was structurally similar with that of VRE2 and VREr5, except 
for an additional 10.8 kb region containing genes which encode for glycopeptide 
resistance proteins, cadmium transporter, and RelB/RelE toxin-antitoxin system. This 
region was flanked by two transposases, suggesting that these additional genes were being 
acquired later by the prophage.  
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CRISPRs are repetitive sequences that, together with CRISPR-associated (cas) genes, 
protect bacteria against integration of exogenous DNA such as phages and plasmids into 
their genomes (Rakus et al., 2007). Clinical E. faecium are known to lack CRISPR loci 
(Palmer and Gilmore, 2010). This probably contributed to the higher rate of exogenous 
DNA in their genomes compared to those of non-clinical E. faecium isolates. No true 
CRISPR was identified in any of the studied strains. Although several CRISPR-like 
regions (designated as questionable CRISPR by CRISPRs Finder) were found, they 
probably carry no functional significance, as suggested by van Schaik et al. (2010).  
 
4.2 Virulence factors  
4.2.1 Virulence genes profiling   
With the increasing incidents of VREfm infections, knowledge on the virulence and 
pathogenicity of this organism is important for disease treatments. Various virulence 
determinants could be identified from the genome sequences of the four studied VREfm 
strains by using the local database of enterococcal virulence genes. The established 
virulence genes such as esp and acm were identified in the genomes of the four strains 
(Table 4.2). Besides, genes encoding endocarditis specific antigen EfaA and a sugar 
transcriptional regulator BopD were also detected in the Malaysian VREfm strains. 
Additionally, these strains also harbored two capsule-related genes, cpsA and cpsB, which 
may provide them with resistance against phagocyctosis in the host cells. An epa operon 
consists of 15 genes previously reported in E. faecium (Qin et al., 2012) was also 
determined. Apart from that, several genes encoding E. faecium surface proteins (fms) 
were also identified (Table 4.2). However, the gelE gene encoding gelatinase associated 
with biofilm formation was not identified in the four genomes. Similarly, hylEfm which 
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encodes for a glycoside hydrolase putatively involved in host colonization (Rice et al., 
2009) was also not detected in any of the studied strains. 
Although the four VREfm strains shared a similar set of virulence genes (Table 4.1), 
differences were still observed between the strains. For example, VREr6 and VREr7 
differed from other two strains through the absence of the fms21-fms20 gene cluster. On 
the other hand, VREr5 harboured a bee-like locus which was not detected in other 
analyzed strains. These putative virulence genes were responsible for the attachment of 
pathogen to both biotic and abiotic surfaces, which could be essential in the persistence 
and pathogenesis of E. faecium.  
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Table 4.2: Selected virulence-associated genes identified in the four Malaysian VREfm strains. 
Gene Function Strain 
VRE2 VREr5 VREr6 VREr7 
esp  Biofilm formation + + + + 
acm Collagen binding + + + + 
gelE Biofilm formation - - - - 
HylEfm Colonization/invasion - - - - 
efaA Adherence + + + + 
ebpABCfm locus Biofilm-formation + + + + 
bee locus Biofilm formation - + - - 
pilA (fms21)-fms20 locus Adherence  + + - - 
fms11-19-16 locus Adherence + + + + 
fms14-17-13 Adherence + + + + 
fms18 (ecbA) Adherence + + + + 
fms15 Adherence + + + + 
bopD Biofilm formation + + + + 
epa operon (epaA, epaB, epaC, epaD, 
epaE, epaF, epaG, epaH, epaL, epaM, 
epaN, epaO, epaP, epaQ,  epaR) 
Biosynthesis of cell-
surface polysaccharides 
+ + + + 
cpsA Antiphagocytosis  + + + + 
cpsB Antiphagocytosis + + + + 
 
        “+” indicates the presence of virulence genes whereas “-” indicates the absence of virulence genes.  
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4.2.2 Biofilm formation 
The biofilm forming ability of the four VREfm strains was determined using crystal 
violet assay. Based on the interpretation scheme adopted from Stepanović et al. (2000), 
VREr5 was the only strain that was able to form biofilm (Table 4.3). To further confirm 
this result, CLSM was performed. The acquired images showed that VREr5 formed dense 
biofilm after 48hr of incubation (Figure 4.5), supporting the results observed from the 
crystal violet assay. Interestingly, unlike VRE2 and VREr6 which could not form biofilm, 
VREr7 was observed to form thin monolayer in the CLSM image acquired. This 
observation is possibly due to the different abiotic surfaces used to grow biofilm in the 
crystal violet assay and for CLSM imaging. The effect of different abiotic substrates on 
bacterial biofilm formation had been demonstrated in other study (Tendolkar et al., 2004). 
 
Table 4.3:  Average results of three replicates of the crystal violet assay to determine 
biofilm forming potential 
Strain OD590 Interpretation* 
VRE2 0.016 Non-biofilm producer 
VREr5 1.780 Strong-biofilm producer 
VREr6 0.049 Non-biofilm producer 
VREr7 0.083 Non-biofilm producer 
* Interpretation based on ODc of 0.218.  
The cut-off OD (ODc) was defined as three standard deviations above of the mean OD of 
the negative control. The biofilm forming ability of each strain was scored as follow: OD 
≤ ODc = non-biofilm producer, ODc < OD ≤ (2x ODc) = weak-biofilm producer, (2x 
ODc) < OD ≤ (4x ODc) = moderate-biofilm producer, OD > (4x ODc) = strong-biofilm 
producer (Chelvam et al., 2014; Stepanović et al., 2000). 
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Figure 4.5: CLSM images of the four Malaysian VREfm strains grown in TSB. Each 
image represents the “flatten” three-dimensional (3D) Z-projection of stack images of A) 
VRE2, B) VREr5, C) VREr6, and D) VREr7. The non-biofilm formers (VRE2, VREr6) 
were either scattered around or formed small aggregates on the glass slide. VREr7 formed 
thin monolayer whereas VREr5 formed dense biofilm.  
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4.2.3 E. faecalis bee homolog 
Since VREr5 was the only biofilm former, further analysis was performed to identify 
unique gene(s) that might contribute to this varying phenotype. Examination on the list 
of unique genes of VREr5 revealed a five-gene cluster which was homologous to the bee 
(biofilm enhancer in enterococcus) locus of E. faecalis.  
In E. faecalis, the bee locus composes of five genes: bee-1, bee-2, bee-3, str1, and str2. 
The three bee genes encode for putative cell wall-anchor proteins whereas the two str 
genes encode for sortases. Insertion mutation of the bee-2 gene shows 70% reduction of 
biofilm formation in E. faecalis strain E99, indicating positive association of this gene 
cluster to biofilm formation (Tendolkar et al., 2006).  
The unique gene-cluster of VREr5 shared approximately 99% amino acid identity with 
Bee-2, Bee-3 and the two sortase proteins of the bee locus but only 39% amino acid 
identity with Bee-1. Despite its low amino acid similarity, the structure of the putative 
Bee-1 homolog of VREr5 was similar to that of the Bee-1 protein. These included a region 
from residues 705 to 810 that showed low degree of similarity (E=1.08e-03) to collagen 
binding B domain of Staphylococcus aureus, and a region from 338 to 469 that encodes 
for the Von Willebrand factor type A (VWA) domain. Given the observed sequence and 
structural similarity, the bee homolog of VREr5 might serve the same role as that found 
in E. faecalis.  
Coburn et al. (2010) reported that the bee locus of E. faecalis is located on a large 
conjugative plasmid. To study the location of the bee homolog of VREr5, PCR for the 
determination of bee-1, bee-2 and bee-3 gene was performed, using both total and plasmid 
DNA as the templates. The results showed that all the three genes were being amplified 
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with the expected amplicon sizes on both total and plasmid DNA (Figure 4.6), suggesting 
that this locus most probably located on a plasmid.  
 
 
 
 
 
 
Figure 4.6: PCR results showing amplification of bee-1, bee-2 and bee-3 gene using total 
and plasmid DNA as template. Lane M: 100bp Molecular marker; lane 1: bee-1_total 
DNA (382bp); lane 2: bee-1_plasmid DNA (382bp); lane 3: bee-1_negative control (no 
DNA added); lane 4: bee-2_total DNA (569bp); lane 5: bee-2_plasmid DNA (569bp); 
lane 6: bee-2_negative control (no DNA added); lane 7: bee-3_total DNA (532bp); lane 
8: bee-3_plasmid DNA (532bp); lane 9: bee-3_negative control (no DNA added) 
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4.3 Antibiotic resistance  
4.3.1 Antibiotic susceptibility profile 
The antibiotic susceptibility profiles of the four analyzed strains is shown in Table 4.4. 
The results showed that these strains were resistant to most of the antibiotics tested. All 
of them were resistant to ampicillin, kanamycin, streptomycin, erythromycin, 
clindamycin and tetracycline. VRE2 was susceptible to gentamicin, whereas the other 
three strains showed high-level resistance to gentamicin (M.I.C > 256 µg/ml). VRE2 and 
VREr5 showed intermediate resistance to teicoplanin whereas VREr6 and VREr7 were 
resistant to the antibiotic. All four strains were susceptible to linezolid. The MIC values 
indicated that all of them were highly resistant to vancomycin (M.I.C > 256 µg/ml).  
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Table 4.4: Antimicrobial resistance profile and the presence of corresponding resistance genes. 
 VAN TEC KAN GEN STM 
 R/I/S vanA R/I/S vanZ R/I/S aac(6')-Ii aph(3')-
III 
R/I/S aac(6')-
aph(2'') 
R/I/S ant(6)-
Ia/aadE 
VRE2 R + I + R + + S - R + 
VREr5 R + I + R + + R + R + 
VREr6 R + R + R + + R + R + 
VREr7 R + R + R + + R + R + 
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Table 4.4 continued 
 
 
 
 
 
Resistance gene(s) or mutation associated with each antibiotic is (are) listed below the abbreviations of respective antibiotics. VAN: vancomycin, TEC: 
teicoplanin, KAN: kanamycin, GEN: gentamicin, STM: streptomycin, AMP: ampicillin, ERY: erythromycin, CLI: clindamycin, TET: tetracycline, LZD: 
linezolid. Plus (+) and minus (-) signs indicate presence and absence of the resistance genes or mutation, respectively. The R/I/S column gives information 
regarding the susceptibility of each strain to respective antibiotics: R = resistant, I = intermediate, S = susceptible.  
 
 AMP ERY CLI TET LZD 
 R/I/S Mutated 
pbp5 
R/I/S ermB R/I/S msrC R/I/S tetS tetM R/I/S G2576T mutation 
in 23S rRNA 
VRE2 R + R + R + R + - R - 
VREr5 R + R + R + R + - R - 
VREr6 R + R + R + R - + R - 
VREr7 R + R + R + R - + R - 
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4.3.2 Antibiotic resistance determinants  
Enterococci can be resistant to virtually all antibiotics commonly found in the clinical 
settings. The underlying antibiotic resistance mechanisms of this organism can be 
intrinsic or acquired through mutation of the intrinsic resistance genes or through 
horizontal acquisition of the resistance determinants. 
Both vanA and vanB are the predominant genes that confer acquired vancomycin 
resistance in enterococci. VanA phenotype is characterized by high level of inducible 
resistance to both vancomycin and teicoplanin whereas VanB phenotype shows inducible 
resistance to vancomycin but variable resistance to teicoplanin (Arthur & Courvalinn, 
1993; Hollenbeck & Rice, 2012). All the local VREfm strains carried the vanA gene, which 
was validated through PCR (Figure 4.7). Despite carrying the vanA genotype, only VRE2 
and VREr5 displaced VanA phenotype (vancomycin MIC > 256 µg/ml, teicoplanin MIC 
=16 µg/ml). In contrast, VREr6 and VREr7 were VanB phenotype-vanA genotype VRE 
strains (vancomycin MIC > 256 µg/ml, teicoplanin MIC =8 µg/ml). The impairment of 
teicoplanin resistance in vanA genotype VRE strains can be due to point mutations of 
vanS or disruption of vanY or vanZ (Gu et al., 2009; Hashimoto et al., 2000). However, 
no mutations or disruptions of these regions were observed in VREr6 and VREr7. Further 
analysis is needed to identify the cause of this impairment. 
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Figure 4.7: PCR results showing amplification of vanA gene. Lane M: 100bp molecular 
marker; lane 1: VRE2; lane 2: VREr5; lane 3: VREr6; lane 4: VREr7; lane 5: negative 
control (no DNA added).  
 
The vanA-carrying Tn1546 transposon varies structurally among strains (Gagnon et 
al., 2011; Huh et al., 2004; Willems et al., 1999). This polymorphic nature of the 
transposon has been employed in molecular typing of VRE to understand the 
dissemination of vancomycin resistance (Huh et al., 2004; Willems et al., 1999). 
Structural analysis revealed that the Tn1546-like transposons of the four studied strains 
were similar. All of them carried a truncated orf1 which encodes a transposase. One 
IS1216V was found to be inserted directly before orf2. Moreover, insertion of an IS1251 
was observed in the intergenic region of vanS and vanH. The structure observed 
resembled type F reported by Willems et al. (1999).  
Resistance to aminoglycoside is commonly observed in VRE strains. High-level 
resistance to aminoglycoside is mediated by three types of aminoglycoside modifying 
enzymes: N-Acetyltransferases (AAC), O-Adenyltransferases (ANT), and O-
500bp 
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  M           1           2            3            4           5 
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phosphotransferases (APH) (Hollenbeck & Rice, 2012). Three genes of these enzymes, 
ant(6)-Ia, aac(6')-Ii and aph(3')-III were found in all four VREfm strains. aac(6')-Ii 
confers low level intrinsic resistance to tobramycin and kanamycin whereas ant(6)-Ia and 
aph(3')-III confer acquired resistance to streptomycin and kanamycin, respectively. The 
ant(6)-Ia (also known as aadE) is part of the multi-resistant cluster of ant(6)-sat4-aphA, 
where sat4 confers resistance to streptothricin. In addition, a bifunctional gene, aac(6')-
aph(2''), which confers high-level acquired resistance to  gentamicin was also detected. 
VRE2 was the only strains that did not harbor the bifunctional gene. This might explain 
its susceptibility towards gentamicin (M.I.C = 4µg/ml). In contrast, the other three strains 
were highly resistant to gentamicin (M.I.C > 256µg/ml). 
E. faecium is intrinsically resistant to β-lactam drugs through the expression of low-
affinity penicillin-binding protein 5 (PBP5). However, acquisition of β-lactamase or 
mutation of pbp5 can contribute to increased resistance of the antibiotic. Four β-
lactamases were identified in each of the studied strains. These included two from 
metallo-β-lactamase superfamily, one putative class C β-lactamase and one from 
unknown-class β-lactamase. Besides, mutations in pbp5 which associated with high-level 
β-lactam resistance in E. faecium were also observed. These mutations included an 
insertion of a serine residue at position 466, after a serine residue; replacement of 
methionine at position 485 to alanine and replacement of glutamic acid at position 629 
by valine. All these mutations have been demonstrated to increased MICs of β-lactam 
drugs (Rice et al., 2004).  
The four local strains carried ermB gene which is associated with erythromycin 
resistance. Furthermore, the msrC gene encoding an ABC efflux pump for macrolides 
and streptogramin B (Singh et al., 2001) was also identified in all the studied strains. 
VRE2 and VREr5 harbored tetS gene whereas VREr6 and VREr7 carried tetM gene. Both 
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these genes confer tetracycline resistance through ribosomal protection (Charpentier et 
al., 1993; Martin et al., 1986).  
 
4.4 Transcriptomic analysis   
4.4.1 Biofilm developmental stage after 24 hours of growth  
A number of enterococcal infections are associated with difficult-to-treat biofilm-
mediated infections, such as those associated with indwelling medical devices, urinary 
catheters, orthopaedic implants, and endocarditis (Donlan et al., 2002). As such, 
understanding the biofilm forming mechanism, especially during the transition from 
planktonic to biofilm cells, is useful in controlling biofilm-associated diseases.  
Since previous CLSM analysis (Figure 4.5) showed that VREr5 formed mature biofilm 
after 48 hr of growth, it was speculated that a shorter incubation time might correspond 
to the initial stage of biofilm formation. VREr5 biofilm was therefore grown for only 24 
hr and the actual developmental stage was visualized using CLSM. The result showed 
that after 24hr of incubation, VREr5 formed cell aggregates that were loosely packed 
(Figure 4.8). This result indicated that at 24 hr of growth, VREr5 was in the initial stage 
of biofilm formation where cell attachment and aggregation occur.  
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Figure 4.8: CLSM image of the biofilm formed by VREr5 after 24 hr of incubation. The 
image represents the “flatten” three-dimensional (3D) Z-projection of stack images 
acquired. VREr5 formed cell aggregates that were loosely packed at 24 hr of growth.  
 
 
4.4.2 Transcriptome assembly and annotation 
After removing the adaptors and low-quality sequences, a total of 7,786,583 to 
11,913,906 reads were generated. Due to the lack of an appropriate reference genome, de 
novo assembly was performed, which generated a total of 1,234 transcripts. The 
assembled transcripts ranged from 301bp to 134,410bp, with an average of 2,887bp. From 
these transcripts, 2,851 coding sequences (CDSs) were generated. Out of the 2,851 CDSs, 
2,833 (99.3%) were matched to the known protein sequences of the Nr database (Table 
4.5).  
Gene Ontology (GO) terms were subsequently assigned to the obtained CDSs. A total 
of 2,404 (84.3%) CDSs were assigned (Table 4.5). 1257 (44.09%) CDSs were in the 
cellular component category, 2001 (70.19%) CDSs were in the molecular function 
category, and 1832 (64.26%) CDSs were in the biological process category. Apart from 
that, a total of 629 (22%) CDSs were mapped to the KEGG pathways, with majority of 
65 
 
the CDSs mapped to the biosynthesis of antibiotics, purine metabolism, pyrimidine 
metabolism, and the glycolysis/gluconeogenesis pathways. To further study the 
functionality of the transcriptome, the annotated CDSs were also classified into different 
functional groups based on the COG database. Among the 2,851 CDSs, 2,411 (84.5%) 
were categorized into 19 COGs (Table 4.5). The largest functional group was “function 
unknown”, which comprised of 559 (22.9%) CDSs, followed by “carbohydrate transport 
and metabolism” (301, 12.33%), “transcription” (207, 8.48%), “replication, 
recombination and repair” (195, 8%), and “cell wall/membrane/envelope biogenesis” 
(164. 6.72%) (Figure 4.9).  
 
Table 4.5: Summary of annotations of the assembled CDSs in VREr5 
Database Number of CDSs Percentage  
Nr 2,833 99.3% 
GO 2,404 84.3% 
KEGG 629 22.0% 
COG 2,411 84.5% 
Total CDSs 2, 851 100% 
 
 
 
 
 66 
 
 
Figure 4.9: COG distribution of the assembled CDSs. The x-axis represents the number of CDSs whereas the y-axis represents the COG categories. The 
largest functional group is the COG group S (Function unknown) whereas the smallest group is COG group N (Cell motility). 
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4.4.3 Transcriptional profiles of biofilm cells 
Principal component analysis (PCA) is a statistical approach to simplify a 
multidimensional data set into a new set of variables (the principal components) which 
explain the key differences of the original data set (Abdi & Williams, 2010). This 
technique has been used in the analysis of gene expression data (Guilhen et al., 2016; 
Hilsenbeck et al., 1999). In this study, PCA revealed that the first principal component 
(PC 1) and the second principal component (PC 2) accounted for approximately 65.5% 
and 31.0% of the total variance of the data set, respectively (Figure 4.10). This result 
clearly indicated that cells in the planktonic and biofilm conditions exhibited different 
gene expression profiles. These differences were also depicted in the heat map generated 
from the clustering of all the six samples based on their relative distance calculated using 
Manhattan distance (Figure 4.11). Due to the large variance observed as compared to 
other planktonic samples, P5 was excluded for the later analysis. To ensure equal numbers 
of samples were used in the following comparison, B1, one of the biofilm samples which 
showed slightly higher variance, was excluded for the later analysis as well.  
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Figure 4.10: Principal component analysis (PCA) of gene expression in biofilm and 
planktonic cells. PCA was performed with the normalized expression values of the 2,851 
CDSs. Each dot indicates a biological replicate. Green dots (B1, B2, B3) represent the 
biofilm samples, whereas red dots (P1, P4, P5) represent the planktonic samples. 
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Figure 4.11: Heat map depicting the gene expression level of the six samples (three 
biological replicates for each growth condition). B1, B2, and B3 represent the biofilm 
samples whereas P1, P4, and P5 represent the planktonic samples. The bar color reflects 
the gene expression level from low (black), medium (red), to high (yellow). The 
dendrogram shows the clustering of the six samples based on similarity of their 
transcription patterns.  
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The transcriptome of the biofilm vs planktonic phase cells showed that a total of 776 
genes were differentially expressed (|fold change |> 2, FDR-adjusted P-value < 0.001). 
Among these, 177 genes were up-regulated whereas 599 genes were down-regulated. 
COG analysis revealed that majority of the up-regulated genes were related to replication, 
recombination and repair (33 genes), carbohydrate transport and metabolism (23 genes), 
and transcription (13 genes). Moreover, genes classified as COG class S (function 
unknown) also represented a considerable part (29 genes) of the up-regulated genes.  
A large proportion of the genes that were being induced in the biofilm mode were those 
that encode for transposase, recombinase and integrase, with fold change of up to 5.23 
relative to the planktonic counterpart (Table 4.6). Apart from that, genes that were 
associated with plasmid replication were also up-regulated for 4.82 fold. Additionally, 
the expression of ebpABC encoding pilus subunit proteins increased by 2.52 fold. Several 
other genes putatively encoding cell wall anchor proteins, such as those carrying the 
LPXTG domain, were also up-regulated. Furthermore, the tetS gene encoding tetracycline 
resistance protein was also up-regulated for approximately three fold. Interestingly, two 
genes associated with quorum sensing, fsr and luxS, were highly down-regulated, with 
fold change of -133.2 and -35.9, respectively (Table 4.7). Moreover, the expression level 
of three genes, arcABC, which involves in arginine catabolism, decreased by 287.52, 
259.23, and 96.1, respectively. The spx gene, which encodes for protein generally 
involves in oxidative stress response was also down-regulated for approximately 12 fold. 
Several other genes that are previously known to involve in enterococcal biofilm 
formation were either not differentially expressed or down-regulated. For example, the 
esp, acm, and sgrA, were not differentially expressed whereas the sagA and altEfm were 
down-regulated. The RNA-seq results were validated by qPCR using selected up- and 
down-regulated genes (Table 4.8).  
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Table 4.6: Selected up-regulated genes in biofilm relative to planktonic cells 
Feature ID Annotation FDR p-value Fold 
change 
Gene.2189 IS6 family transposase 1.25E-30 5.23 
Gene.1209 Plasmid replication initiation 5.91E-28 4.82 
Gene.1210 Hypothetical protein 1.38E-26 4.75 
Gene.417 Transposase 7.79E-26 4.36 
Gene.458 Integrase 5.99E-25 4.25 
Gene.889 Recombinase 8.65E-23 3.94 
Gene.457 Plasmid replication protein repR 1.61E-21 3.89 
Gene.888 DNA recombinase 6.05E-19 3.53 
Gene.1866 Transposase for insertion sequence 
element IS256 in transposon 
2.06E-17 3.29 
Gene.1712 Transposase 4.13E-17 3.21 
Gene.462 Tetracycline resistance tetS 1.40E-14 2.99 
Gene.991 LPXTG-domain-containing cell wall 
anchor domain 
1.47E-17 2.83 
Gene.398 Phage head-tail adaptor 9.27E-08 2.81 
Gene.1333 Initiator RepB plasmid replication 
protein 
2.96E-13 2.74 
Gene.2506 von Willebrand factor (EbpA) 8.54E-19 2.52 
Gene.2511 Cell surface protein EbpB 1.78E-12 2.47 
Gene.2523 AraC family transcriptional regulator 2.24E-12 2.38 
Gene.2287 Hypothetical protein 2.24E-06 2.34 
Gene.914 TcpC-containing conjugal transfer 
protein 
5.39E-11 2.32 
Gene.435 Mannonate dehydratase 4.13E-16 2.29 
Gene.2509 Cell surface protein EbpC 1.73E-13 2.26 
Gene.2436 PTS mannose transporter subunit IID 9.20E-09 2.24 
Gene.895 Amino acid transporter 8.28E-17 2.2 
Gene.2682 MarR family transcriptional regulator 2.48E-06 2.17 
Gene.2102 Cell surface protein 8.70E-09 2.15 
Gene.1013 GntR family transcriptional regulator 4.32E-11 2.12 
Gene.2215 ABC transporter permease 6.46E-13 2.11 
Gene.956 Hypothetical protein 6.81E-11 2.09 
Gene.1296 LPXTG-domain-containing cell wall 
anchor protein 
1.25E-10 2.08 
Gene.902 Glucuronate isomerase 2.69E-13 2.06 
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Table 4.7: Selected down-regulated genes in biofilm relative to planktonic cells 
 
 
 
 
 
 
 
Feature ID Annotation FDR p-value Fold 
change 
Gene.802 Arginine deiminase ArcA 3.09E-219 -287.52 
Gene.805 Ornithine carbamoyltransferase ArcB 2.04E-217 -259.23 
Gene.813 Carbamate kinase ArcC 2.71E-186 -96.1 
Gene.502 Accessory regulator FsrB 8.83E-198 -133.22 
Gene.1015 Alkyl hydroperoxide reductase subunit 
C 
1.39E-111 -43.47 
Gene.1973 C4-dicarboxylate anaerobic carrier 3.1E-144 -39.89 
Gene.1598 S-ribosylhomocysteinase LuxS 5.53E-96 -35.99 
Gene.138 Universal stress protein 4.82E-116 -27.56 
Gene.1755 Bee-3-like protein 8.98E-124 -26.91 
Gene.2579 Sugar ABC transporter ATP-binding 2.21E-30 -21.6 
Gene.1616 Alpha-glycerophosphate oxidase 2.26E-48 -19.43 
Gene.1549 NADH peroxidase 4.98E-82 -17.53 
Gene.1761 Peptidase (Bee-2) 2.35E-95 -15.33 
Gene.2143 Lactose-specific phosphotransferase 
enzyme IIA component 
6.5E-84 -15.3 
Gene.139 Regulatory Spx 0 -12.04 
Gene.1978 Ribosomal S1 4.46E-57 -11.81 
Gene.622 Formate acetyltransferase 7.7E-31 -11.55 
Gene.1500 ATP-dependent Clp protease ATP-
binding subunit 
6.38E-46 -9.66 
Gene.1752 VWA domain-containing (bee-1) 1.76E-71 -9.15 
Gene.1291 Flavin reductase 2.32E-69 -8.4 
Gene.1111 dTDP-glucose 4,6-dehydratase 2.4E-34 -8.03 
Gene.1363 Secreated antigen SagA 7.34E-24 -6.07 
Gene.2727 Acetyltransferase 8.82E-72 -5.87 
Gene.553 Autolysin Alt 1.22E-08 -2.05 
Gene.1113 Glucose-1-phosphate 
thymidylyltransferase 
2.44E-08 -2.02 
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Table 4.8: Expression levels of selected up- and down-regulated genes in planktonic 
and biofilm cells as measured by qPCR. 
Gene  Expression level in planktonic 
cells* 
Expression level in biofilm cells 
ebpA 1 ± 0.013 1.357 ± 0.012 
tetS 1 ± 0.038 1.657 ± 0.073 
repR 1 ± 0.013 1.449 ± 0.067 
arcA 1 ± 0.309 0.647 ± 0.102 
fsrB 1 ± 0.071 0.859 ± 0.050 
bee-2 1 ± 0.096 0.613 ± 0.300 
 
*The expression level of each of the six genes were defined with respect to that of the 
planktonic cells, defined as 1.  
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CHAPTER 5: DISCUSSION 
5.1 Whole genome sequencing  
The advent of next generation sequencing technology enables the whole genome 
sequences of bacteria to be determined in a faster and cost effective manner. Decoding 
the genomes of pathogens enabled the evaluation of their basic genomic features, 
virulence potential, and resistance mechanism, which are useful for infection control. 
Although many E. faecium genomes have been sequenced, there is still a lack of genome 
data from Southeast Asia, especially from the clinically important VREfm. In this study, 
four VREfm strains isolated from a tertiary hospital in Malaysia were selected based on 
the previous PFGE results. VREr6 and VREr7 isolated from patient Y displaced identical 
PFGE patterns. However, the PFGE profile of VREr5, which was also isolated from 
patient Y, was more similar to that of VRE2 isolated from another patient, patient X. In 
order to better elucidate the genetic differences, these strains were subjected to whole 
genome sequencing.  
In silico MLST analysis classified the four strains into two sequence types: VRE2 and 
VREr5 belonged to ST80, whereas VREr6 and VREr7 belonged to ST203. These two 
sequence types are grouped under CC17, confirming the clinical importance of the four 
analyzed strains. Strains belonging to ST203 are commonly reported, including in 
Malaysia (Cha et al., 2012; Getachew et al., 2013; Lam et al., 2013; Yu et al., 2015). 
According to the records from the PubMLST database (last accessed on 23rd Jan 2017) 
(Homan et al., 2002), 49 entries on ST203 were found and are mainly represented by 
strains distributed in European (49%) and Asia Pacific countries (51%). In Australia, 
ST203 has been reported to replace ST17, the major founder of CC17, signifying the 
increasing clinical importance of this specific sequence type (Lam et al., 2013). In 
contrast, ST80 is rarely reported as compared to ST203. There were only 13 entries of 
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ST80 in the MLST database (last accessed on 23rd Jan 2017) which are mainly European 
strains, except for two entries with Asian strains. To the best of our knowledge, this study 
is the first to report ST80 VRE strain in Malaysia. The identification of ST80 has provided 
new insight into the dissemination of the high-risk CC17 in Malaysia. A study including 
more local strains will be useful to determine the prevalence and potential clinical 
significance of ST80 in Malaysia.  
Consistent with the PFGE and MLST results, the comparative genomics analysis 
suggested that VREr6 and VREr7 have substantial variations from VRE2 and VREr5. 
The genomic contents of the four strains were further scrutinized to discover genes that 
may distinguish these two groups in terms of fitness and adaptive advantage. Two such 
genes were identified: a gene cluster encodes for myo-inositol metabolism proteins found 
only in both VRE2 and VREr5 and a gene encoding bacteriocin, lactococcin 972 (Lcn 
972), found only in both VREr6 and VREr7.  
Myo-inositol is commonly found in soil and can be used as a sole carbon source in 
various microorganisms such as Rhizobium leguminosarum (Fry et al., 2001) and Bacillus 
subtilis (Yoshida et al., 2008). Although several studies had been carried out on the 
biochemistry of this pathway, information on the molecular genetics of this pathway in 
bacteria is limited to B. subtilis. In B. subtilis, the myo-inositol catabolism pathway is 
mediated by the iol divergon that comprises of the operon iolABCDEFGHIJ and iolRS 
(Yoshida et al., 2008). The net result of this pathway creates acetyl-CoA which can 
participate in the citric acid cycle to generate energy. Hence, the ability to catabolize myo-
inositol can be advantageous in conditions where other sugar sources are limited, such as 
in infected host where the rate of nutrient competition is high. The myo-inositol level is 
higher in blood and urine of patients with diabetes and diabetic-associated renal diseases 
(Hong et al., 2012). Therefore, pathogens that possess the ability to catabolize this sugar 
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have additional growth advantage to outcompete other bacteria in a diabetic patient. 
Although the functionality of the genes encoding inositol metabolism proteins identified 
in VRE2 and VREr5 was unknown, the fact that patient Y is a diabetic patient suggested 
the possible association of these genes in providing extra fitness to VREr5.  
Bacteriocins are peptides produced by an organism to inhibit the growth of its closely 
related species (Héchard & Sahl, 2002). Lcn972 is known as an atypical nonlantibiotic 
bacteriocin which is heat sensitive and highly hydrophilic (Martínez et al., 1996). Instead 
of targeting the cytoplasmic membrane and forming pores, Lcn972 inhibits septum 
formation which leads to deformation and eventually lysis of cells (Martinez et al., 2000). 
Further study on the mechanistic action of this bacteriocin revealed that Lcn972 acts by 
interacting with cell wall precursor lipid II, which is the primary docking site for 
lantibiotics prior to pore formation (Martinez et al., 2008). Lcn972 is the first 
nonlantibiotic that specifically interacts with lipid II. Besides, Lcn972 also plays a role in 
the induction of prophages, although it is limited to specific prophage/host system 
(Madera et al., 2009). With its role in killing closely-related strains, the presence of 
Lcn972 in both VREr6 and VREr7 may increase the competitiveness of these two strains 
in colonizing and subsequently infecting the host. 
The genomic differences among the four VREfm strains were further supported by the 
phylogenomic tree constructed. In concordance with the PFGE results, VREr5 was 
distantly related to VREr6 and VREr7 but was more closely related to VRE2. Apart from 
demonstrating the relationship among the local strains, the phylogenomic analyses using 
strains from CC17 also revealed a divergent of strains from ST17, ST18, and ST87 into 
two clusters. Members of the CC17 was initially thought to evolve from a single founder 
(ST17) based on the eBURST algorithm (Willems et al., 2005). However, this concept 
was later suggested to be erroneous by Turner et al. (2007). This group showed that the 
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reliability of eBURST to correctly infer ancestor-descendent link decreases in species 
with a high recombination to mutation ratio, such as in the case of E. faecium. This implies 
that hospital-associated strains which were previously grouped under CC17 might not be 
derived from a single founder, but possibly evolved independently from different 
ancestral strains. Subsequent analyses of the MLST data using Bayesian modelling 
method from the Bayesian analysis of genetic population structure (BAPS) software 
revealed that the three major ST of hospital-associated strains (ST17, ST18, ST78) were 
placed into different BAPS groups, with ST78 in BAPS 2-1 and ST17 and ST18 in BAPS 
group 3-3 (Willems et al., 2012). The result obtained from this study was in line with the 
BAPS analysis, supporting the idea that CC17 is not monophyletic.  
Although PFGE, MLST, and phylogenomic analyses showed that VREr6 and VREr7 
were clonally related, these two strains had diversified considerably. In addition to the 
differences in genome contents observed from the presence of strain-specific genes, the 
gain and/or loss of mobile genetic elements also plays a significant role in determining 
the genome dynamics of the two strains. This highlights the discriminatory power of 
WGS in detecting fine differences of the same clone and hence provides a better 
resolution in distinguishing strains with high genetic similarity. 
Based on the available clinical data, patient Y underwent EVD and nasogastric tube 
exchange after the isolation of VREr5. Both procedures involved the insertion of catheters 
into the body. Together with the results obtained from the PFGE, MLST, phylogenomic, 
and comparative genomics analyses, the clinical data suggested that patient Y was 
probably infected by strains from different lineages. The two medical procedures might 
have introduced new VREfm strains to the patient through contaminated catheters or from 
hands of healthcare workers, thereby explaining the differences observed between 
VREr5, the initial strain isolated from patient Y, and the subsequent two strains, VREr6 
78 
 
and VREr7. Moreover, since patient Y was admitted when patient X was still in the 
hospital, the genetic similarity between VRE2 and VREr5 suggested that VRE2 could 
have persisted and spread in the hospital. 
 
5.2 Virulence factors 
A number of known and potential virulence factors were identified in the genomes of 
the four Malaysian strains. The presence of these virulence factors might explain the 
persistence of these organisms in the hospital settings. Furthermore, the identification of 
the esp gene in all the four genomes further confirm the previous notion that this virulence 
gene is significantly enriched in the clinical isolates (Abriouel et al., 2008; Willems et al., 
2001).  
Surface expressed proteins such as pili and microbial surface components recognizing 
adhesive matrix molecules (MSCRAMM) have been implicated in adherence, biofilm 
formation, and host tissue invasion in Gram-positive bacteria (Maisey et al., 2008; 
Nallapareddy et al., 2011). A total of 15 genes having the MSCRAMM features, such as 
the immunoglobulin-like fold, were previously identified in E. faecium TX16 
(Nallapareddy et al., 2003; Sillanpää et al., 2009, 2008). Of these, 11 of them are grouped 
into four different clusters: ebpAfm-ebpBfm-ebpCfm, fms11-fms19-fms16, fms14-fms17-
fms13, and fms21-fms20. Among these, the ebpABCfm gene cluster encodes for biofilm-
associated pili and is important in urinary tract infection in an animal model 
(Nallapareddy et al., 2011). On the other hand, the fms21 (pilA) has been shown to form 
a pilus-like structure in E. faecium but its association to pathogenesis remains unknown 
(Hendrickx et al., 2008). In a study performed by Kim et al. (2010), the fms21-fms20 
cluster was found to be located on a large transferable plasmid (Kim et al., 2010). Hence, 
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VRE2 and VREr5 probably acquired this gene cluster horizontally, although the role of 
these genes in the virulence of these strains is unknown.  
Cell surface polysaccharides can play an important role in the virulence and phagocytic 
resistance of Gram-positive bacteria. In E. faecalis, the epa gene cluster is involved in the 
production of an antigenic cell wall polysaccharide composed of rhamnose, glucose, 
galactose, N-acetylgalactosamine and N-acetylglucosamine (Teng et al., 2009). This gene 
cluster is important in biofilm formation, phagocytic resistance and tissue invasion in E.  
faecalis (Teng et al., 2009; Zeng et al., 2004). Similar gene cluster has been reported in 
E. faecium (Qin et al., 2012). However, the epa locus of E. faecium differs from that of 
E. faecalis in terms of the genes number (18 in E. faecalis, 15 in E. faecium) and order 
(Qin et al., 2012). Due to these differences, the polysaccharide synthesized by the 
products of E. faecium epa locus may have different sugar contents from that of E. 
faecalis. Nevertheless, the production of cell surface polysaccharides can provide 
pathogens with resistance against phagocytosis, enabling them to survive and persist in 
the host environment.  
Despite the identification of several biofilm-associated genes in the four genomes, 
VREr5 was the only biofilm former among the studied strains. This observation suggested 
that the previously known biofilm-associated genes, such as esp and ebpABCEfm, might 
not play a role in biofilm formation in the four local VREfm strains. Alternatively, a 
combination of multiple factors and genes might be needed for the expression of biofilm 
phenotype in these strains. The presence of a strain-specific bee-like locus, for instance, 
may be an important factor in the complex regulatory system that contributes to the 
biofilm forming ability of VREr5.  
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5.3 Antibiotic resistance  
The occurrence of VREfm has received much attention in public health, mainly because 
this organism is resistant to multiple available drugs commonly used in the hospitals. 
Despite its own intrinsic resistance to antibiotics such as penicillin and kanamycin, VREfm 
also possesses a remarkable ability to acquire resistance genes through either 
chromosomal mutations or genetic exchange of mobile elements.   
Due to the clinical importance of VREfm, the vancomycin resistance mechanism has 
been widely studied. At present, nine types of vancomycin resistance (VanA, VanB, 
VanC, VanD, VanE, VanG, VanL, VanM, and VanN) have been described in enterococci 
(Boyd et al., 2008; Courvalin, 2006; Lebreton et al., 2011; Xu et al., 2010). Among these, 
the VanA and VanB types are the most commonly reported. Although widely distributed, 
the VanA type resistance is mainly found in strains originated from the United States, 
Europe, and Korea (Bonten et al., 2001; Yoo et al., 2006). On the other hand, VanB type 
resistance is more commonly found in Australia and Singapore (Lam et al., 2013; Molton 
et al., 2013). In Malaysia, the occurrence of clinical strains with VanA type resistance has 
been reported (Ibrahim et al., 2010; Mohamed et al., 2015). Although rare, VanB VRE 
has been isolated from a healthy animal-affiliated worker in Malaysia (Getachew et al., 
2012). The identification of four vanA-carrying VREfm in this study suggested that VanA 
type VRE might be more prevalent in the clinical strains in Malaysia.  
There have been reports documenting the discrepancies observed between the 
genotype and phenotype of vanA-genotype VRE. The differences observed are mainly 
due to the impairment of teicoplanin resistance which leads to the emergence of VanB 
phenotype-vanA genotype VRE (Il et al., 2008; Kuo et al., 2014; Song et al., 2006). 
Hashimoto et al. reported three point mutations in the sensor domain of vanS which 
contribute to impaired teicoplanin resistance among the vanA-genotype strains 
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(Hashimoto et al., 2000). Another study demonstrated that deletion of vanY and vanZ 
genes or insertion of ISEfa4 at the orf2-vanR intergenic region may also responsible for 
the differences between genotype and phenotype (Gu et al., 2009). However, these 
mutations or gene disruptions were not observed in the Tn1546-like transposons of 
VREr6 and VREr7. Instead, the Tn1546-like transposons of these two strains were similar 
to those found in VRE2 and VREr5, which displaced VanA phenotype. Hence, the actual 
cause of the impaired teicoplanin resistance warrants further investigation. Apart from 
that, the similar Tn1546-like transposons carried by the four studied strains indicated a 
possible resistance pool in the hospital. Since no VRE strain was isolated from patient X 
and patient Y at the point of admission, these patients most probably acquired VRE during 
their prolonged hospitalization, which carried the same Tn1546-like transposons.  
The anaerobic respiration of E. faecium has been thought to limit the uptake of 
aminoglycosides which contributes to its intrinsically low-level resistance to these drugs 
(Bryan & Van Den Elzen, 1977). Hence, a combination therapy involving 
aminoglycosides and drugs that disrupt cell wall synthesis, such as ampicillin or 
vancomycin, is effective in enhancing the therapeutic effect (Moellering & Weinberg, 
1971). However, this synergistic effect becomes ineffective when the strain is highly 
resistant to aminoglycosides, especially gentamicin and streptomycin. The acquisition of 
the bi-functional gene aac(6´)-Ie-aph(2´´)-Ia confers high-level resistance to gentamicin 
by modifying the 2´ hydroxyl position of the antibiotic (Ferretti et al., 1986). More 
importantly, the presence of this gene also renders E. faecium resistant to virtually all 
clinically available aminoglycosides, except streptomycin (Chow, 2000). Therefore, 
streptomycin is a drug of choice in the combination therapy against stains possessing the 
aac(6´)-Ie-aph(2´´)-Ia gene, providing that these strains are not highly resistant to 
streptomycin (MIC ≥ 1000 μg/ml). High-level resistance to streptomycin is mainly 
determined by the presence of ant(6´)-Ia. Since three (VREr5, VREr6, VREr7) of the four 
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Malaysian strains harboured both the aac(6´)-Ie-aph(2´´)-Ia and ant(6´)-Ia genes, it was 
speculated that the synergistic therapy mentioned earlier cannot effectively eradicate 
these strains. Instead, the use of linezolid might help to clear VRE infecting patient Y, 
given that all the three strains were phenotypically resistant to linezolid and did not 
possess the mutations that confer resistance to this drug.  
Except for the observed VanB phenotype-vanA genotype in VREr6 and VREr7, the 
antibiotic resistance determinants identified corresponded well with the antibiotic 
resistance phenotypes of the four local VREfm. The determination of resistance genes or 
mutations enables further understanding of the resistance mechanisms employed by the 
specifically studied strains. This could be useful in deciding the appropriate therapeutic 
dosage of the antibiotics, as well as the development of new treatment methods.   
 
5.4 Transcriptomic analysis  
Biofilm is a surface-attached community encased in a matrix of exopolymeric 
substances. Biofilm formation is a complicated developmental process which involves 
the attachment and immobilization on a surface, formation of microcolony, and 
development of three-dimensional structure (O`Toole et al., 2000). It has been 
demonstrated that the gene expression profiles of bacteria grown in biofilm and 
planktonic mode are different (Beenken et al., 2004; Resch et al., 2005). Determination 
of genes that are required for biofilm formation at different stages can, therefore, be 
helpful in controlling the biofilm development, which is important for therapeutic 
purposes.  
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The high-throughput sequencing technology generated a total of 1,234 transcripts, 
representing a comprehensive transcriptome for VREr5, the only biofilm former among 
the studied strains. Functional annotation showed that the transcripts obtained were 
involved in almost all of the biological processes. However, a large portion of them was 
with unknown functions, indicating the limitation in fully understand the transcriptome 
of this organism. The assembly of raw reads was performed de novo, due to the lack of 
an appropriate reference genome. Reads were later aligned to the generated assembly to 
assess the integrity and reliability of the assembly. Approximately 99.2% of the raw reads 
from each sample mapped to the assembled transcripts, indicating that the de novo 
assembly was performed accurately.  
The transition from a free-swimming lifestyle to a surface-attached community-based 
growth requires the sensing of environmental cues that prompt cells to change their form 
of life. This shift in lifestyle involves extensive changes in structure and function which 
governed by a complex regulatory network. Several genes related to transcriptional 
regulators were up-regulated in the early stage of biofilm formed by VREr5. Most of the 
transcriptional regulators, such as those from the AraC, MerR, Gnt, and MarR family, are 
associated with carbon metabolism, stress response, and virulence (Gallegos et al., 1997; 
Perera & Grove, 2010). The higher gene expression levels of these proteins might due to 
the need to respond to environmental signals that trigger the biofilm initialization process, 
followed by the synthesis of sugars and energy to prepare for the next step of biofilm 
development. Although the exact roles of most of the up-regulated transcriptional 
regulators cannot be inferred in the current study, the results indicated the involvement 
of specific regulatory systems in the control of specific stages of biofilm formation.  
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Attachment to a surface is the first step in biofilm development. Therefore, it is not 
surprising to find out that the expression of genes related to adherence was up-regulated 
in the biofilm of VREr5. Most of these genes encoded for LPXTG-domain-containing 
cell wall anchor proteins, which are well-known in their role for attachment, catalyzed by 
the cleavage of sortase (Konto-Ghiorghi et al., 2009; Paterson & Mitchell, 2004). One 
up-regulated gene cluster which encoded such proteins was the pili-encoding ebpABCfm. 
Prior to the discovery of ebpABCfm, similar gene cluster (ebpABC) had been found in E. 
faecalis and its association with biofilm formation was demonstrated (Nallapareddy et 
al., 2006). Sillanpää et al. (2008) later identified the three-gene locus ebpABCfm in E. 
faecium which shows 48-74% similarity with that found in E. faecalis (Hendrickx et al., 
2008). Deletion of ebpABCfm eliminates cell surface expression of the encoded pili and 
significantly reduces both biofilm formation and initial adherence, indicating a positive 
association of this gene cluster to biofilm formation (Sillanpää et al., 2010). The induction 
of ebpABCfm observed in VREr5 further supported the involvement of this locus in the 
biofilm development of E. faecium. 
The tetracycline resistance gene tetS had also been over-expressed in the biofilm cells. 
Apart from providing resistance against tetracycline, the induction of tetS might also 
associated with protein synthesis needed during biofilm formation. It has been 
demonstrated that protein synthesis is important for the attachment step of biofilm growth 
(Crouzet et al., 2014; O’Toole & Kolter, 1998). Since tetS confers tetracycline resistance 
through ribosomal protection (Charpentier et al., 1993), this action might indirectly 
ensure normal synthesis of proteins required for the initial step of biofilm formation. 
Ironically, the expression levels of genes encoding ribosomal proteins were lower in the 
biofilm cells as oppose to the planktonic cells. This could be attributed to a lower growth 
rate in cells grown in biofilm as compared to the free-floating mode (Rice et al., 2000). 
The reduced growth rate of biofilm cells can be supported by the decreased expression of 
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genes encode for DNA replication and metabolism proteins in the transcriptomic results. 
Similarly, the lower expression of ribosomal genes observed could be due to a slower rate 
of protein synthesis in the biofilm cells.  
A higher level of horizontal gene transfer is a well-established phenomenon in the 
biofilm (Madsen et al., 2012). The up-regulation of several genes related to transposase 
and recombinase in VREr5 further confirm the established observation. Furthermore, the 
increased expression of genes encoding competence proteins in the biofilm formed by 
VREr5 supported the existence of genetic exchange event in the analysed stage of biofilm 
formation. Besides, the result obtained in this study also indicated that the increased rate 
of horizontal gene transfer can occur as early as the initial step of biofilm formation. 
However, this exchange of genetic materials is not one directional. Horizontal gene 
transfer, such as conjugative transfer of plasmids, can also influence biofilm formation. 
A study conducted by Ghigo (2001) showed that the capacity of biofilm formation was 
greatly enhanced in E. coli introduced with a conjugative F plasmid. Other studies also 
demonstrated enhanced biofilm formation in E. coli by other conjugative plasmids 
(Burmølle et al., 2008; Ong et al., 2009). All of the above studies indicated the role of 
conjugative pili in the biofilm development of Gram negative bacteria by either 
promoting cell aggregation or enhancing attachment to a surface. While conjugation of 
Gram positive bacteria is pili-independent, the close interaction between the donors and 
recipients can have similar effect as the conjugative pili in promoting cell aggregation, 
which in time may lead to biofilm formation. Alternatively, plasmids that carry biofilm-
associated-pili might also be transferred to the recipient cells, leading to activation or 
enhancement of biofilm formation. Although gene associated with the conjugal transfer 
was up-regulated, the transfer of pilus-containing plasmid cannot be confirmed in VREr5. 
However, given the up-regulation of several genes associated with cell wall-anchored 
proteins, the conjugative transfer of pilus-carrying plasmids cannot be ruled out.  
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Apart from the interplay observed between conjugative plasmids and biofilm 
formation, another effect of biofilm on plasmid biology is the plasmid copy number. In 
the biofilm formed by VREr5, a number of genes associated with plasmid replication 
were found to be over-expressed, indicating active replication of plasmid. As early as in 
1995, the interconnection between biofilm and the plasmid copy number had been 
observed (Davies & Geesey, 1995). A later study performed by May et al. (2009) showed 
that the copy number of pBR322, a plasmid carrying ampicillin and tetracycline resistance 
genes, increased in biofilm cells of E. coli as compared to in planktonic cells. The author 
also demonstrated that the increased copy number of plasmid correlates with increased 
antibiotic resistance (May et al., 2009). Similarly, in E. faecalis, the copy number of 
different types of plasmid was also found to be increased in cells growing in a biofilm 
(Cook et al., 2011; Cook & Dunny, 2013). It is postulated that the increased copy number 
of plasmid in biofilm cells could be related to the release of the extracellular DNA. It was 
reported that extracellular DNA has been substantially secreted during the early biofilm 
growth of E. faecalis by a cell-lysis-independent mechanism (Barnes et al., 2012). Cook 
and Dunny, therefore, propose that if chromosome, instead of plasmid, is secreted to the 
extracellular matrix, the fraction of cellular RNA polymerase available for plasmid genes 
will increase relative to that of the chromosome, thereby increasing the transcription of 
plasmid genes (Cook & Dunny, 2014). Although the hypothesis made by Cook and 
Dunny (2014) has not yet been confirmed, our observation that genes associated with 
plasmid replication was up-regulated during the early stages of biofilm formation can be 
informative for further development of the hypothesis. Furthermore, since the gene 
expression of the pasmid-encoded tetS is also increased in the biofilm cells, the up-
regulation of plasmid replication genes might responsible for enhanced antibiotic 
resistance by increasing the number of plasmid carrying the tetS gene.   
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Several genes involved in the pentose and glucuronate interconversion pathway also 
displaced increased expression under biofilm condition. These included genes encode for 
mannonate dehydratase and glucuronate isomerase. The mannonate dehydratase 
catalyzes the conversion of D-mannonate to 2-keto-3-deoxy-D-gluconate (Rakus et al., 
2007). The resultant product serves as a substrate for the pentose phosphate pathway, 
which ultimately generates energy and five-carbon sugars (Wahba et al., 1960). The 
enzyme glucuronate isomerase, on the other hand, catalyzes the conversion of D-
glucuronate to D-fructuronate (Ashwell et al., 1960). The D-fructuronate can eventually 
be converted to D-mannonate and enters the pentose phosphate pathway as mentioned 
earlier (Wahba et al., 1960). The biofilm cells might then use the products from the 
pentose phosphate pathway to synthesize purines and pyrimidines, the two building 
blocks of nucleic acids. Given the high rate of plasmid replication in the initial stage of 
biofilm formation, the induction of both mannonate dehydratase and glucuronate 
isomerase seems to play an important role in generating substrates for the DNA 
replication. This observation also indicated that the metabolic pathway is regulated in the 
biofilm cells in respond to specific requirement during different stages of growth. 
Quorum sensing is a cell-density dependent signaling system used by many bacteria 
species in biofilm formation (Annous et al., 2009). Quorum sensing is mediated by 
chemical molecules called autoinducers produced by bacteria. Binding of autoinducers to 
the specific transcriptional regulator(s) leads to either activation or repression of target 
genes. Both Gram-positive and Gram-negative bacteria possess a common quorum 
sensing system mediated by autoinducer 2 (AI-2). The production of AI-2 depends on a 
gene called luxS (Surette et al., 1999). This gene was found to be under-expressed in 
biofilm formed by VREr5. Several studies show that the luxS quorum sensing system has 
different effects on bacterial biofilm formation. For example, in Streptococcus gordonii, 
a luxS mutant failed to form mixed-species biofilm as compared to the wild-type strain 
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(McNab et al., 2003). Other studies show that deletion of luxS leads to altered biofilm 
structure (He et al., 2016; Merritt et al., 2003). Furthermore, the positive association of 
this quorum sensing system to biofilm formation had been demonstrated in both E. 
faecalis and Streptococcus pneumoniae (Shao et al., 2012; Vidal et al., 2013). 
Nevertheless, there are studies indicating that luxS suppresses biofilm formation (Sela et 
al., 2006; Xu et al., 2006). In VREr5, the down regulation of luxS suggested that this 
quorum sensing system might play a negative regulatory role in biofilm formation, similar 
to those reported by Sela et al. and Xu et al.  
Another quorum sensing related gene found in enterococci is fsr. In E. faecalis, the fsr 
locus consists of three genes: fsrA (response regulator), fsrB (signalling peptide), and fsrC 
(histidine kinase). This locus regulates the expression of gelatinase and serine proteases, 
which contributes to biofilm formation by facilitating bacterial attachment to a surface 
(Hancock & Perego, 2004). Interestingly, the expression level of fsrB gene in the biofilm 
of VREr5 decreased 133.22 fold. It was found out that the fsr system does not always 
positively regulates biofilm formation in enterococci. In a study performed by Mohamed 
and Murray (2006), the introduction of fsr locus into a gelE-negative strong biofilm 
producer reduces biofilm production at 41% compared to the wild type. The same result 
has been observed with a medium biofilm former (Mohamed & Murray, 2006). These 
observations indicate that the fsr locus plays a different role in biofilm formation 
independent of the activation of gelatinase production. The author, therefore, suggested 
that in the absence of gelatinase, fsr might negatively control initial attachment, leading 
to reduced biofilm formation (Mohamed & Murray, 2006). Since VREr5 was gelatinase-
negative, as shown by results obtained in Section 4.3.1, the decreased expression of fsrB 
in biofilms suggested that this locus might also negatively regulate biofilm growth in 
VREr5. In this case, fsrB could be the major player in the negative regulation of biofilm 
formation as fsrA and fsrC were not differentially expressed. 
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Biofilm cells are known to have a higher tolerance to environmental stresses than its 
free-living counterpart. A global transcriptional regulator, Spx (spx), is known to 
participate in several stress responses. Spx was initially identified in Bacillus subtilis as 
a suppressor of two proteases, ClpP and ClpX (Nakano et al., 2001). In B. subtilis, Spx 
supresses competence development while activates genes involved in oxidative stress 
responses (Nakano et al., 2003a, 2003b). In E. faecalis, this protein was shown to be 
involved in a variety of stress responses, where deletion of spx impaired growth of the 
bacterium under oxidative and antibiotic stresses, as well as higher killing rate by 
macrophage compared to the wild type (Kajfasz et al., 2012). However, this protein does 
not seem to play a role in general stress response in the biofilm of E. faecium strain VREr5 
as the gene encoding it was under-expressed. Nevertheless, spx has been shown to 
negatively affect biofilm formation in both S. aureus and S. epidermidis. In both cases, 
spx acts to supress the ica operon encoding polysaccharide intracellular adhesin, leading 
to reduced primary attachment and, hence, biofilm formation (Pamp et al., 2006; Wang 
et al., 2010). In the same sense, spx in VREr5 might either supress a biofilm-related gene 
or more during the planktonic growth. When a decision to move into biofilm mode is 
made, the transcription of spx decreased, relieving the suppression. Wang et al. (2010) 
demonstrated that the protease ClpP involves in biofilm formation of S. epidermidis by 
degrading Spx. As such, one would expect the expression level of clpP gene to be 
increased in the biofilm cells. However, clpP was down-regulated in VREr5. This implied 
that clpP may not be involved in the spx-mediated biofilm formation of VREr5. 
Alternatively, the down-regulation of clpP may be due to the presence of an 
autoregulatory system which is activated when the level of substrate (Spx) is below the 
threshold.   
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A gene cluster encodes for putative proteins of the arginine deiminase system 
(arcABC) was among the most highly down-regulated genes in the biofilm of VREr5. 
This result was different from other studies which show that the arcABC is expressed at 
a higher level in biofilm cells relative to that in the planktonic cells (Beenken et al., 2004; 
Resch et al., 2005). Despite the differences observed, this gene cluster has been shown to 
be more active during the maturation of biofilm (Lindgren et al., 2014; Resch et al., 2005). 
When the biofilm matures, some regions become anoxic due to the enclosed matrix. In 
these regions, cells respire through fermentation, producing acids. The accumulation of 
acids leads to acid stress which can be alleviated by the arcABC operon. The arcABC 
operon converts arginine to ornithine, ammonia, and carbon dioxide (Cunin et al., 1986). 
The resultant ammonia is then protonated into ammonium ion (NH4+) which increases the 
intracellular pH, maintaining pH homeostasis (Lindgren et al., 2014). During the initial 
stage of biofilm formation, however, cells are still being supplied with sufficient nutrients 
and oxygen for energy production through aerobic respiration. Hence, the arginine 
deiminase system is probably not needed during the early stage of biofilm formation, 
which might explain the under expression of the arcABC in VREr5.  
The bee locus of E. faecalis has been shown to enhance biofilm formation. This five-
gene locus is located on a conjugative plasmid and encodes for proteins carrying 
conserved domains (B domain, von Willebrand factor type A domain, LPxTG domain) 
that are involved in ligand binding and cell wall anchoring (Tendolkar et al., 2006). 
Biofilm formation was greatly reduced (70%) when bee-2, one of the five genes, was 
inactivated. Furthermore, filter mating experiment showed that the transconjugants 
displaced enhanced biofilm-forming ability compared to the parent strain, confirming the 
role of this locus in biofilm formation of E. faecalis (Tendolkar et al., 2006). Interestingly, 
although the previous genomic study suggested a possible association of a homolog of E. 
faecalis bee locus to biofilm formation in VREr5, this unique gene locus was down-
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regulated. This suggested that the bee homolog might have a negative regulatory role in 
the biofilm development of VREr5. Further investigations are needed to study the 
association of this gene cluster to biofilm formation in VREr5 as well as in other E. 
faecium strains.   
The transcriptome results also showed that some genes putatively involved in 
enterococcal biofilm formation, such as esp, acm, and sgrA, were not differentially 
expressed. The role of esp in enhancing biofilm formation in both E. faecalis and E. 
faecium has been reported (Heikens et al., 2007; Tendolkar et al., 2004). However, other 
studies suggested that esp is not required or sufficient for biofilm formation in E. faecalis 
and E. faecium (Dworniczek et al., 2005; Ramadhan & Hegedus, 2005). For acm and 
sgrA, both of these genes have been implicated in the biofilm formation of E. faecium 
(Hendrickx et al., 2009; Nallapareddy et al., 2008). The results obtained from the 
transcriptomic study of VREr5 suggested that the involvement of these genes in 
enterococcal biofilm development is either strain-specific, as observed for esp, or that 
these genes were only needed in the later stage of biofilm formation in VREr5. The latter 
postulation was supported by the under-expression of altEfm and sagA, which encode for 
an autolysin and secreted protein, respectively, that have been shown to participate in the 
maturation of biofilm (Paganelli et al., 2015, 2013).  
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CHAPTER 6: CONCLUSION 
In this study, four clinical VREfm strains isolated from a tertiary hospital in Malaysia 
were subjected to whole genome sequencing and comparative genomics analyses. These 
four strains were previously shown to have different PFGE patterns, particularly three 
strains from a single patient (patient Y). The comparative genomics analysis indicated 
genetic variability among the four local strains, contributed mainly by mobile genetic 
elements and their respective strain-specific genes. Nevertheless, high genetic similarity 
was observed between VREr6 and VREr7, both isolated from patient Y. On the other 
hand, VREr5, the initial isolate from patient Y, was found to be genetically more similar 
to VRE2 isolated from an index case (patient X).  Subsequent MLST and phylogenomics 
analyses further revealed that VREr5 was different from the other two strains isolated 
from the same host. Both the clinical and genomic data suggested that patient Y was most 
probably infected with multiple strains of VREfm from different clones. Additionally, the 
first isolated strain from patient Y was probably of the same clone as the strain from the 
index case, patient X. By having the whole genome sequences, the genetic relationship 
of the four local VREfm strains, previously determined through PFGE, was able to be 
elucidated with higher resolution. Furthermore, the genome sequences also enable the 
identification of a number of antibiotic resistance- and virulence genes in the VREfm 
strains, which could contribute to their persistence and pathogenicity. A unique bee-like 
locus was identified only in VREr5, which may associate with biofilm formation. This 
study, to the best of knowledge, is the first report on the comparative genomics analyses 
of local VREfm as well as the first to report ST80 VREfm in Malaysia.  
On the other hand, the transcriptomic analysis performed in this study had provided 
insight into the gene expression profile of the initial stage of biofilm formation in E. 
faecium. High-quality transcripts were generated which enable reliable interpretation of 
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the genes that participate in different growth conditions. Genes that were induced in the 
biofilm cells involved mainly in surface adherence, plasmid replication, conjugation, and 
sugar metabolism. The up-regulation of these genes correlated with the requirements 
during the initial step of biofilm formation, in which attachment to a surface, cell-cell 
interaction, and energy production are important. Moreover, the over-expression of 
several transcriptional regulators indicated that cells possess specific regulatory system 
in controlling the different stages of biofilm development. Additionally, the 
transcriptomic analysis also revealed the down-regulation of genes that participate or 
possibly needed in the latter stage of biofilm formation, suggesting that the results 
obtained in this study clearly reflected the initial stage of biofilm development. The 
unique bee-like locus was found to be down-regulated, indicated a negative association 
of this gene to the biofilm initiation of VREr5. The transcriptomic data generated from 
this study can be useful in understanding the biofilm forming mechanism of E. faecium, 
which in turn may be helpful in developing new drugs against biofilm-related 
enterococcal diseases.  
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APPENDICES 
Appendix 1: Media, Buffers, and Solutions  
Brain heart infusion broth 
Brain heart infusion broth                                     14.8g 
Distilled water up to                                              400ml 
Autoclave at 121°C for 15min. 
 
Brain heart infusion agar 
Brain heart infusion agar                                       18.8g 
Distilled water up to                                              400ml 
Autoclave at 121°C for 15min. 
 
Tryptic soy broth (TSB) 
Tryptic soy broth                                                    12.0g 
Distilled water up to                                               400ml 
Autoclave at 121°C for 15min. 
 
Mueller-hinton (MH) II agar 
Mueller-hinton agar                                      8.4g 
Distilled water up to                                               400ml 
Autoclave at 121°C for 15min. 
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Tryptic soy broth (TSB) + 1% glucose 
Tryptic soy broth                                                    12.0g 
Glucose                                                                     4.0g 
Distilled water up to                                               400ml 
Autoclave at 121°C for 15min. 
 
Sodium chloride (0.85%) 
Sodium chloride                                                     3.4g 
Distilled water up to                                              400ml 
Autoclave at 121°C for 15min. 
 
1X Phosphate buffered solution (PBS) 
PBS tablet                                                               1 tablet 
Distilled water                                                        100ml 
Autoclave at 121°C for 15min. 
 
1 M Tris, pH 8.0 [molecular weight = 121.44g] 
Tris                                                                          48.45g 
Deionized water                                                      360ml 
The pH of the solution was adjusted to pH8.0 by adding concentrated HCl, top up with 
deionized water to 400ml. Autoclave at 121°C for 15min. 
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0.5M Ethylenediaminetetraacetic acid (EDTA), pH 8.0 [molecular weight = 372.44g] 
EDTA                                                   74.44g 
Deionized water                                    360ml 
The pH of the solution was adjusted to pH8.0 by adding concentrated HCl, top up with 
deionized water to 400ml. Autoclave at 121°C for 15min. 
 
Tris-EDTA (TE) buffer (10mM Tris: 1mM EDTA, pH 8.0) 
1M Tris, pH 8.0                                      10ml 
0.5M EDTA, pH 8.0                                2ml 
Deionized water to                                  1000ml 
Autoclave at 121°C for 15min. 
 
Cell suspension buffer (100mM Tris, 100mM EDTA, pH 8.0) 
1M Tris, pH 8.0                                        10ml 
0.5M EDTA, pH 8.0                                 20ml 
Deionized water to                                    1000ml 
Autoclave at 121°C for 15min. 
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10% Sarcosyl (N-Lauryl-Sarcosine [Molecular weight = 293.30g]) 
Sodium N-lauroyl-sarcosinate solution      10ml 
Deionized water to                                      100ml 
Autoclave at 121°C for 15min. 
 
Cell lysis buffer (50mM Tris, 50mM EDTA, pH 8.0 + 1.0% Sarcosine) 
1.0M Tris, pH 8.0                                        25ml 
0.5M EDTA, pH 8.0                                    50ml 
10% Sarcosyl                                               50ml 
Deionized water to                                       500ml 
Autoclave at 121°C for 15min. 
 
10X Tris-Borate EDTA buffer (TBE), pH 8.3 
Trizma base                                                 121.1g 
Othoboric acid                                             61.8g 
EDTA (Ultra-Pure Grade)                           0.745g 
Deionized water to                                      1000ml 
The pH of the stock solution was adjusted to pH 8.3 and autoclaved. It was then diluted 
to 0.5X for routine use. Autoclave at 121°C for 15min. 
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0.5X TBE 
10X TBE                                                      50ml 
Deionized water                                           950ml 
 
1.0% Seakem gold agarose  
Seakem gold agarose                                   0.1g 
TE buffer                                                     10ml 
 
1.5% Agarose for PCR 
LE Agarose powder                                     1.5g 
0.5X TBE buffer                                          100ml 
 
1.0% Crystal violet solution 
Crystal violet powder                                   0.1g 
Distilled water                                              10ml 
 
80:20 Ethanol-acetone 
Ethanol                                                        80ml 
Acetone                                                       20ml 
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Appendix 2: Strains’ information 
 
 
 
 
 
  VRE2 VREr5 VREr6 VREr7 
Patient X Y Y Y 
Isolation date 17-Jan-2011 4-Mar-2011 12-Mar-2011 18-Mar-2011 
Isolation site Blood CSF Blood Urine 
Genome size 
(bp) 2862609 2898367 3014993 3021201 
GC% 37.85 37.8 37.61 37.6 
CDS 2853 2906 3049 3057 
tRNA 55 55 58 58 
rRNA 3 3 3 3 
Sequence type 
(ST) 80 80 203 203 
Clonal 
complex 17 17 17 17 
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 Appendix 3: Strains used in phylogenomic analysis 
Strain 
Genbank 
accession number Country Source 
Sequence 
type 
Clonal 
complex 
Aus0085 CP006620.1 Australia Blood 203 17 
Aus0004 CP003351.1 Australia Blood 17 17 
TX16 CP003683.1 USA Blood 18 17 
E1133 AHWR00000000.1 USA Faeces 117 17 
E155 AUWX00000000.1 USA Faeces 17 17 
E1904 AHXQ00000000.1 Netherlands Urine 210 17 
E0120 AHWI00000000.1 Netherlands Patient’s ascites 27 17 
E2560 AHYI00000000.1 Netherlands Blood 78 17 
E1185 AHWS00000000.1 France Blood 26 17 
E161 JXZA00000000.1 China Urine 414 17 
LCT-
EF128 AJUP00000000.1 China 
Bronchoalveolar 
lavage 160 17 
E1731 AHXO00000000.1 Africa Blood 18 17 
E6045 AHYL00000000.1 Portugal 
Hospitalized 
patient 78 17 
E1392 AHWV01000046 UK 
Hospitalized 
patient 64 17 
E0333 AHWL00000000.1 Israel Blood 80 17 
VRE84 AIVF00000000.1 Denmark Human 17 17 
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Appendix 4: PCR primers and cycling conditions 
Primer Sequence (5’-3’) Cycling condition Target Amplicon 
size (bp) 
vanA-F CATGAATAGAATAAAAGTTGCAATA Initial denaturation step of 5 min at 94°C; 30 
cycles of 1 min at 94°C, 1 min at 54°C, 1 min 
at 72°C; and a final elongation step of 10 min 
at 72°C 
vanA 1030 
vanA-R CCCCTTTAACGCTAATACGATCAA 
Bee-1F TCCCGCAAATCTTGACTGCT  
Initial denaturation step of 10 min at 95°C; 35 
cycles of 30 s at 94°C, 30 s at 54°C, 60 s at 
72°C; and a final elongation step of 10 min at 
72°C 
bee-1 382 
Bee-1R ACAGCTTGTGTTCCATCCGT 
Bee-2F GTGGGACCAAGCACCTGATG bee-2 569 
Bee-2R TCGCCGTACCGATCAAAAGAA 
P101D12-1 CAAGATAAGCATCTGTTACATCATAGGCTG bee-3 532 
Bee-12 CGGACAAAGAATTAGCTACCGTTCAC 
ESP 14F AGATTTCATCTTTGATTCTTGG Initial denaturation step of 10 min at 95°C; 30 
cycles of 30 s at 94°C, 30 s at 58°C, 30 s at 
72°C; and a final elongation step of 10 min at 
72°C 
esp 510 
ESP 12R AATTGATTCTTTAGCATCTGG 
AcmF1 GATTTTTGAGAGATGATATAGTAG Initial denaturation step of 10 min at 95°C; 30 
cycles of 30 s at 94°C, 30 s at 53°C, 30 s at 
72°C; and a final elongation step of 10 min at 
72°C 
acm 1600 
AcmR1 ATTCTCATTTGTAACGACTAGC 
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Appendix 5: Primers for gap closing and sequencing of Tn1546-like transposon  
Primer  Sequence (5’-3’) 
5235.F ATA TCA CGT TGG ACA AAG C 
7035.R TTA CGT CAT GCT CCT CTG AG 
4511R TCG GAG CTA ACC ACA TTC 
ISV650F ACC TTC ACG ATA GCT AAG GTT 
ISV132R AGG ATT ATA TAA GAA AAC CCG 
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Appendix 6: Primers for qPCR 
Primer Sequence (5’-3’) Product size (bp) 
arcA-F TTA GCG GCA GAA GCG ATT GA 165 
arcA-R ACG AAC CCC AGC CAT GAT TT 
fsr-F TGG GCG GAA ACA GGA ATC AC 133 
fsr-R TCA TCA CCA AGG GAA CGC C 
bee2-F ATC GAA GGG GTC GGC TTT AC 207 
bee2-R AAC CGC ATT TTT ACC GCC AC 
ddl-F TTG CCT GGC GAA GTC GTA AA 162 
ddl-R TCC GCT TCC ACC TAA CAT CG 
ebpA-F AAC GGT GCA GTA CAG ATG GG 171 
ebpA-R ACC ATC CGT CAG CAA AAC GA 
tetS-F CGC TAT GGG TGT GAA CAA GG 109 
tetS-R TTC GGA AAT CTG CTG GCG TA 
repR-F ACG TTG TTC GCG AGG GTT AT 137 
repR-R AGA GGG TTC AAG GGG GTT GA 
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Appendix 7: Supplementary data 
a) DNA sequencing BLAST result of vanA 
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b) DNA sequencing BLAST result of bee-1 homolog* 
 
*bee-1 homolog of VREr5 has low identity with that found in E. faecalis. The sequenced 
region represents the homologous region between the two genes. The E. faecalis bee locus 
is found in plasmid pBEE99.  
 
 
 
 
 
 
 
128 
 
c) DNA sequencing BLAST result of bee-2 homolog 
 
 
d) DNA sequencing BLAST result of bee-3 homolog 
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e) Complete list of up-regulated genes 
Feature ID Annotation Fold 
change 
FDR-corrected 
p-value 
GO1 KEGG COG2 
Gene.1916  M trans-acting positive regulator 2 5.87E-010 NA NA NA  
Gene.2214  AraC family transcriptional regulator 2 3.47E-008 F; P; C NA K 
Gene.2707  Integrase 2 2.17E-009 F; P NA L 
Gene.970  ATPase 2 6.97E-009 F Purine metabolism S 
Gene.1781  GntR family transcriptional regulator 2.01 4.05E-011 F; P NA K 
Gene.1888  Methyltransferase 2.01 5.24E-008 F; P NA Q 
Gene.2030  M trans-acting positive regulator 2.01 2.54E-013 NA NA S 
Gene.45  D-isomer specific 2-hydroxyacid dehydrogenase 2.01 5.34E-014 F; P Pyruvate metabolism C 
Gene.75  Operon 2 2.01 5.06E-009 F; P Pyrimidine 
metabolism 
F 
Gene.2015  Resolvase 2.02 6.15E-007 F; P NA L 
Gene.2035  Histidine kinase 2.02 1.35E-010 C; P; F NA T 
Gene.2257  Coproporphyrinogen III oxidase 2.02 2.89E-011 P; C; F Porphyrin and 
chlorophyll 
metabolism 
H 
Gene.2710  Transcription antiterminator 2.03 2.96E-013 F; P NA K 
Gene.28  GntR family transcriptional regulator 2.03 8.75E-012 F; P NA K 
Gene.894  ATPase 2.03 7.41E-013 NA NA U 
Gene.136  Competence protein 2.04 3.30E-010 C NA S 
Gene.37  ABC transporter permease 2.04 3.81E-013 C; P; F NA G 
Gene.439  4-phosphoerythronate dehydrogenase 2.04 8.43E-014 F; P Glycine, serine and 
threonine 
metabolism, 
Methane 
C 
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metabolism, 
Biosynthesis of 
antibiotics 
Gene.78  N5-carboxyaminoimidazole ribonucleotide mutase 
(purE) 
2.04 1.09E-009 F; P Purine metabolism, 
Biosynthesis of 
antibiotics 
F 
Gene.2113  Hexulose-6-phosphate isomerase 2.05 1.30E-011 P; F Pyrimidine 
metabolism 
G 
Gene.2185  Transposase 2.05 2.33E-006 F; P NA L 
Gene.2532  MULTISPECIES: hypothetical protein 2.05 4.57E-005     NA 
Gene.982  Mannitol dehydrogenase 2.05 2.28E-013 F; P Pentose and 
glucuronate 
interconversions 
G 
Gene.988  ABC transporter premease 2.05 5.92E-013 F; P; C NA T 
Gene.1149  Hypothetical protein 2.06 1.58E-012 C NA S 
Gene.2530  Two-component system response regulator receiver 2.06 1.20E-011 F; P; C NA T 
Gene.902  Glucuronate isomerase 2.06 2.69E-013 P; F Pentose and 
glucuronate 
interconversions 
G 
Gene.143 Late competence protein 2.07 8.87E-006 C NA NA  
Gene.1455  MULTISPECIES: hypothetical protein 2.07 2.05E-006     NA 
Gene.1875  PTS galactitol transporter subunit IIC 2.07 8.43E-014 F; P; C NA G 
Gene.1999  Integral membrane 2.07 2.31E-008 C; P; F NA S 
Gene.2551  PTS mannose transporter subunit IID 2.07 3.90E-007 C; P; F NA G 
Gene.1296  LPXTG-domain-containing cell wall anchor protein 2.08 1.25E-010 C NA M 
Gene.1795  ABC transporter substrate-binding protein 2.08 7.96E-013 P NA G 
Gene.2204  ATP-binding protein 2.08 1.11E-010 F; P; C NA T 
Gene.2515  Major facilitator superfamily transporter 2.08 3.24E-011 P; C NA G 
Gene.31  ABC transporter substrate-binding protein 2.08 1.06E-010 NA NA G 
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Gene.334 Phage tail tape measure TP901 core region 2.08 3.65E-014 C NA S 
Gene.454  PTS glucitol sorbitol-specific IIA component 2.08 7.46E-010 C; P; F NA G 
Gene.401  Hypothetical protein 2.09 5.20E-004 NA NA NA  
Gene.875  Hypothetical protein 2.09 5.58E-014 NA NA S 
Gene.956  Hypothetical protein 2.09 6.81E-011 NA NA NA  
Gene.1008  Integral membrane 2.1 5.14E-010     S 
Gene.1289  Collagen-binding protein 2.1 1.17E-008 C NA M 
Gene.1786  CCS family citrate carrier protein 2.1 4.04E-013 P; C; F NA C 
Gene.2011  DNA polymerase V 2.1 1.58E-007 P; F Purine metabolism, 
Pyrimidine 
metabolism 
L 
Gene.2104  Nucleotide pyrophosphohydrolase 2.1 3.67E-005     S 
Gene.2123  PTS ascorbate transporter subunit IIB 2.1 6.91E-009 P; F NA G 
Gene.2517  Efflux ABC transporter permease 2.1 8.24E-013 C NA V 
Gene.2689  Resolvase 2.1 4.85E-012 F; P Purine metabolism, 
Pyrimidine 
metabolism 
L 
Gene.340  Phage terminase 2.1 4.75E-011 NA NA S 
Gene.808  Ferrichrome transport system permease 2.1 6.13E-011 C; P; F NA P 
Gene.879  Ribonuclease HI 2.1 2.13E-011 F; P NA L 
Gene.1317  Ammonium transporter AmtB 2.11 3.25E-012 F; P; C NA P 
Gene.144  Competence protein 2.11 4.02E-005 C NA NA  
Gene.2215  ABC transporter permease 2.11 6.46E-013 C; P NA P 
Gene.900  Mannitol dehydrogenase 2.11 6.76E-014 F; P Pentose and 
glucuronate 
interconversions 
G 
Gene.949  Hypothetical protein 2.11 7.76E-014 NA NA NA  
Gene.973  Transglutaminase-like superfamily 2.11 7.49E-012 C NA E 
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Gene.996  Mannonate dehydratase 2.11 1.09E-013 P; F Pentose and 
glucuronate 
interconversions 
G 
Gene.1013  GntR family transcriptional regulator 2.12 4.32E-011 F; P NA K 
Gene.1300  MerR family transcriptional regulator 2.12 1.68E-007 F; P NA K 
Gene.2681  DNA replication protein DnaD 2.12 2.82E-011 NA NA L 
Gene.312  Integrase core domain partial 2.12 1.00E-011 F; P NA L 
Gene.2127  PTS glucitol sorbitol- IIBC component 2.13 7.47E-015 C; P; F  NA G 
Gene.850  Amino acid permease/serine:threonine exchanger 
SteT 
2.13 1.85E-013 C; F; P NA E 
Gene.1279  ISL3 family transposase 2.14 3.14E-012 NA NA L 
Gene.1281  Sortase 2.14 2.15E-008 C NA M 
Gene.2508  alpha-L-rhamnosidase 2.14 2.12E-015 P; F NA S 
Gene.1175  ComF family protein 2.15 1.52E-013 P; F NA S 
Gene.1981  Hypothetical protein 2.15 3.42E-014 NA NA S 
Gene.2102  Cell surface protein 2.15 8.70E-009 C NA NA  
Gene.2109  PTS ascorbate transporter subunit IIC 2.15 8.97E-016 C; P; F NA G 
Gene.69  Hypothetical protein 2.15 1.10E-014 C NA NA  
Gene.2130  Glucitol operon activator/transcriptional regulator 2.16 6.74E-014 NA NA S 
Gene.24  ABC transporter ATP-binding 2.16 5.38E-011 F Purine metabolism P 
Gene.2526  Shikimate dehydrogenase 2.16 1.93E-013 F; P Phenylalanine, 
tyrosine and 
tryptophan 
biosynthesis, 
Biosynthesis of 
antibiotics 
E 
Gene.2567  Hypothetical protein 2.16 8.78E-007 NA NA NA  
Gene.62  Two-component system response regulator receiver 2.16 3.89E-011 F; P; C  NA T 
Gene.2682  MarR family transcriptional regulator 2.17 2.48E-006 F; P; C NA K 
 133 
Gene.1290  DNA-3-methyladenine glycosylase I 2.18 1.95E-010 F; P NA L 
Gene.1329  X-Pro dipeptidyl-peptidase 2.18 2.29E-010 C; F NA S 
Gene.1676  ABC transporter permease 2.18 3.20E-010 C NA NA  
Gene.2128  Short chain dehydrogenase reductase family 
oxidoreductase 
2.18 1.07E-008 F; P Fructose and 
mannose metabolism 
S 
Gene.2283  Restriction endonuclease 2.19 2.40E-004 F; P NA V 
Gene.2711  Carbohydrate deacetylase 2.19 2.20E-014 F; P NA G 
Gene.449  PTS system IIB component 2.19 2.53E-015 C; P; F NA G 
Gene.1258  PTS fructose IIA component 2.2 6.14E-011 C; P; F NA G 
Gene.1283  Sugar ABC transporter ATP-binding 2.2 1.79E-015 C; P NA G 
Gene.895  Amino acid transporter 2.2 8.28E-017 C NA S 
Gene.921  Haloacid dehalogenase 2.2 2.14E-010 NA NA S 
Gene.981  Neopullulanase 2.2 5.62E-014 P; F NA G 
Gene.56  ABC transporter permease 2.22 2.94E-011 C; P NA P 
Gene.2718  Hypothetical protein 2.23 1.59E-013 NA NA NA  
Gene.933  Hypothetical protein 2.23 2.90E-012 NA NA NA  
Gene.2436  PTS mannose transporter subunit IID 2.24 9.20E-009 C; P; F NA G 
Gene.53  ABC transporter permease 2.24 6.02E-014 C; P NA P 
Gene.1316  (gadC) glutamate:gamma-aminobutyrate antiporter 2.25 8.35E-018 C; F; P NA E 
Gene.17  Competence protein comEC/Rec2 2.26 2.74E-018 C; P NA S 
Gene.1810  Two-component system response regulator 2.26 1.44E-011 F; P; C NA T 
Gene.2081  Cell wall surface anchor protein 2.26 1.95E-013 C NA M 
Gene.2509  Cell surface protein ebpC 2.26 1.73E-013 C NA M 
Gene.379  Hypothetical protein 2.26 2.12E-009 NA NA S 
Gene.890  Hypothetical protein 2.26 7.40E-009 NA NA NA  
Gene.2626  Transposase 2.27 4.73E-009 F; P NA L 
Gene.1319  Glutaminase A 2.29 1.46E-013 F; P D-Glutamine and D-
glutamate 
metabolism, 
E 
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Arginine 
biosynthesis, 
Alanine, aspartate 
and glutamate 
metabolism 
Gene.2507  DNA topoisomerase III 2.29 9.54E-013 F; C; P NA L 
Gene.435  Mannonate dehydratase 2.29 4.13E-016 P; F Pentose and 
glucuronate 
interconversions 
G 
Gene.1257  RpiR family transcriptional regulator 2.3 1.11E-015 F; P NA K 
Gene.2220  Response regulator receiver 2.3 1.32E-012 F; P; C NA T 
Gene.906  cro CI family transcriptional regulator 2.3 6.09E-018 P; F NA K 
Gene.396  Hypothetical protein 2.31 6.40E-007 NA NA NA  
Gene.903  MFS transporter 2.31 1.56E-013 P; C; F NA G 
Gene.1156  Transcription antiterminator 2.32 2.26E-015 F; P NA K 
Gene.448  Alcohol dehydrogenase 2.32 3.74E-014 F; P Metabolism of 
xenobiotics by 
cytochrome P450, 
Naphthalene 
degradation, 
Glycine, serine and 
threonine 
metabolism, 
Chloroalkane and 
chloroalkene 
degradation, 
Glycolysis / 
Gluconeogenesis, 
Tyrosine 
metabolism, Retinol 
C 
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metabolism, Fatty 
acid degradation, 
Drug metabolism - 
cytochrome P450, 
Biosynthesis of 
antibiotics, alpha-
Linolenic acid 
metabolism 
Gene.891  LPXTG-domain-containing cell wall anchor 
domain 
2.32 1.33E-017 C NA M 
Gene.914  TcpC-containing conjugal transfer protein 2.32 5.39E-011 C NA S 
Gene.985  Hypothetical protein 2.32 2.23E-009 NA NA NA  
Gene.2024  Bacteriocin-associated protein 2.34 4.57E-015 C NA S 
Gene.2287  Hypothetical protein 2.34 2.24E-006 NA NA NA  
Gene.2420  DNA invertase Pin 2.34 1.79E-009 F; P NA L 
Gene.2421  Integrase 2.35 8.55E-010 F; P NA L 
Gene.1337  Mobilization protein (plasmid) 2.36 4.63E-010 C NA NA  
Gene.947  Hypothetical protein 2.36 4.11E-008 NA NA NA  
Gene.441  Foldase 2.37 6.02E-014 F; P; C NA O 
Gene.2523  AraC family transcriptional regulator 2.38 2.24E-012 F; P NA K 
Gene.2422  IS3 family transposase 2.39 4.14E-010 NA NA L 
Gene.2669  Integrase core domain partial 2.42 2.87E-004 F; P NA L 
Gene.2512  M trans-acting positive regulator 2.45 2.46E-012 NA NA S 
Gene.1342  Hypothetical protein 2.47 7.14E-011 NA NA NA  
Gene.2511  Cell surface protein EbpB 2.47 1.78E-012 C NA M 
Gene.2606  Integrase 2.47 7.55E-011 F; P NA L 
Gene.54  Histidine kinase 2.5 3.31E-016 F; P; C NA T 
Gene.409  Phage terminase 2.51 2.24E-009 NA NA NA  
Gene.2506  von Willebrand factor (EbpA) 2.52 8.54E-019 C NA S 
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Gene.2648  Integrase 2.52 4.87E-019 F; P NA L 
Gene.2013  Plasmid replication initiator A 2.54 6.85E-011 NA NA S 
Gene.1016  Guanylate kinase 2.55 9.81E-019 P; F Purine metabolism F 
Gene.905  Cell division protein FtsK 2.55 1.78E-016 F; C NA D 
Gene.1847  Phage repressor protein 2.61 5.01E-009 NA NA K 
Gene.1951  Hypothetical protein 2.62 6.49E-012 NA NA NA  
Gene.2018  IS3 family transposase 2.63 1.73E-012 NA NA L 
Gene.1496  Replication protein 2.66 8.89E-012 P; F; C Purine metabolism, 
Pyrimidine 
metabolism 
L 
Gene.2546  Cobalt transporter 2.68 6.17E-012 F; P NA L 
Gene.1497  Hypothetical protein 2.69 3.64E-012 NA NA NA  
Gene.1336  Hypothetical protein 2.7 4.72E-013 NA NA NA  
Gene.1288  DUF624 domain-containing protein 2.71 2.36E-020 C NA NA  
Gene.1339  Mobilization protein 2.71 1.17E-011 NA NA S 
Gene.1333  Initiator RepB plasmid replication protein 2.74 2.96E-013 P; F; C Purine metabolism, 
Pyrimidine 
metabolism 
L 
Gene.405  DNA-binding protein 2.79 1.23E-007 F NA K 
Gene.398  Phage head-tail adaptor 2.81 9.27E-008 NA NA NA  
Gene.456  MULTISPECIES: hypothetical protein 2.81 1.56E-012 C NA S 
Gene.991  LPXTG-domain-containing cell wall anchor 
domain protein 
2.83 1.47E-017 C NA NA  
Gene.938  Hypothetical protein 2.92 1.08E-013 NA NA NA  
Gene.1344 Hypothetical protein 2.97 7.39E-015 C NA NA  
Gene.462  Tetracycline resistance tetS 2.99 1.40E-014 F; P NA T 
Gene.1335  MULTISPECIES: hypothetical protein 3.03 5.14E-016 C NA NA  
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Gene.460  Hypothetical protein 3.03 2.10E-014 F; C; P Purine metabolism, 
Pyrimidine 
metabolism 
NA  
Gene.887 Transposase 3.03 3.99E-015 F; P NA L 
Gene.2419  Cell filamentation protein Fic 3.2 7.02E-015 P NA D 
Gene.1712  Transposase 3.21 4.13E-017 F NA L 
Gene.1866  Transposase for insertion sequence element IS256 
in transposon 
3.29 2.06E-017 F; P NA L 
Gene.1948  Replication initiation factor 3.31 3.49E-018 F; P NA NA  
Gene.1947  Recombinase 3.34 2.02E-018 F; C; P NA S 
Gene.2227  Replication initiation factor 3.52 2.17E-019 F; P NA NA  
Gene.888  DNA recombinase 3.53 6.05E-019 F; P NA L 
Gene.2605  Integrase 3.65 1.08E-019 F; P nA L 
Gene.457  Plasmid replication protein RepR 3.89 1.61E-021 F; P Purine metabolism, 
Pyrimidine 
metabolism 
S 
Gene.889  Recombinase 3.94 8.65E-023 F; P NA L 
Gene.458  Integrase 4.25 5.99E-025 F; P NA L 
Gene.641  Transposase 4.31 3.44E-025 F; P NA L 
Gene.1334  Relaxase 4.33 5.14E-026 F; C; P NA U 
Gene.417  Transposase 4.36 7.79E-026 F NA L 
Gene.1338  Bacteriocin precursor 4.71 1.34E-027 C; P NA NA  
Gene.1210  Hypothetical protein 4.75 1.38E-026 NA NA NA  
Gene.1209  Plasmid replication initiation 4.82 5.91E-028 P; F; C Purine metabolism, 
Pyrimidine 
metabolism 
L 
Gene.2189  IS6 family transposase 5.23 1.25E-030 F; P NA L 
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1C, cellular component; P, biological process; F, molecular function; NA, not applicable 
2[D] Cell cycle control, cell division, chromosome partitioning; [M] Cell wall/membrane/envelope biogenesis; [N] Cell motility; [O] Post-translational 
modification, protein turnover & chaperones; [T] Signal transduction mechanisms; [U] Intracellular trafficking, secretion & vesicular transport; [V] 
Defense mechanisms; [J] Translation, ribosomal structure & biogenesis; [K] Transcription; [L] Replication, recombination & repair; [C] Energy 
production & conversion; [G] Carbohydrate transport & metabolism; [E] Amino acid transport & metabolism; [F] Nucleotide transport & metabolism; 
[H] Coenzyme transport & metabolism; [I] Lipid transport & metabolism; [Q] Secondary metabolites biosynthesis, transport & catabolism; [P] 
Inorganic ion transport & metabolism; [S] Function unknown 
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f) Partial list of down-regulated genes  
*Only the first 200 genes are shown here 
Feature ID Annotation Fold 
change 
FDR-corrected 
p-value 
GO1 KEGG COG2 
Gene.802 Arginine deiminase ArcA -287.52 3.09E-219 C; P; F Biosynthesis of 
antibiotics, Arginine 
biosynthesis 
E 
Gene.805  Ornithine carbamoyltransferase ArcB -259.23 2.04E-217 C; F; P Biosynthesis of 
antibiotics, Arginine 
biosynthesis 
E 
Gene.502  Accessory regulator FsrB -133.22 8.83E-198 P; C; F NA  T 
Gene.813  Carbamate kinase ArcC -96.1 2.71E-186 F; P Nitrogen 
metabolism, 
Arginine 
biosynthesis, Purine 
metabolism 
E 
Gene.1407  PTS mannose fructose sorbose IID component -81.2 4.29E-143 C; P; F NA  G 
Gene.1201  Ribosomal Ctc-form -78.1 7.80E-173 F; C; P NA  J 
Gene.1172  Ribosomal subunit interface -68.03 1.91E-155 C; P NA  J 
Gene.1071  MULTISPECIES: hypothetical protein -59.77 1.75E-119 C NA  S 
Gene.790  ATP synthase epsilon chain -45.28 3.66E-134 C; F; P NA  C 
Gene.1182  Membrane protein -43.83 1.73E-125 C NA  S 
Gene.1015  Alkyl hydroperoxide reductase subunit C -43.47 1.39E-111 F; P Phenylpropanoid 
biosynthesis 
O 
Gene.1788  Enolase -42.28 5.25E-114 F; P; C 
comple
Biosynthesis of 
antibiotics, Methane 
G 
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x; 
C:cell 
surface 
metabolism, 
Glycolysis / 
Gluconeogenesis 
Gene.2002  Hypothetical protein -41.31 1.02E-125 NA NA  S 
Gene.1187  PspC family transcriptional regulator -40.26 6.66E-139 C NA  S 
Gene.1973  C4-dicarboxylate anaerobic carrier -39.89 3.10E-144 C NA  S 
Gene.986  Alkyl hydroperoxide F subunit -38.9 7.88E-137 F; C; P Phenylpropanoid 
biosynthesis, 
Glutathione 
metabolism 
O 
Gene.1817  Triosephosphate isomerase -38.59 1.39E-116 P; C; F Inositol phosphate 
metabolism, 
Glycolysis / 
Gluconeogenesis, 
Fructose and 
mannose 
metabolism, Carbon 
fixation in 
photosynthetic 
organisms, 
Biosynthesis of 
antibiotics 
G 
Gene.1413  PTS system mannose-specific IIC component -37.69 1.44E-116 C; P; F NA  G 
Gene.1404  PTS mannose fructose sorbose IIB component -37.14 2.70E-111 C; P; F NA  G 
Gene.1100  Tryptophan-rich sensory -36.3 7.22E-121 C NA  T 
Gene.1598  S-ribosylhomocysteinase LuxS -35.99 5.53E-096 P; F Cysteine and 
methionine 
metabolism 
T 
Gene.1801  Glyceraldehyde-3-phosphate dehydrogenase -35.86 1.21E-111 F; P NA  G 
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Gene.1791  Phosphoglycerate kinase -34.99 2.22E-114 F; C; P Glycolysis / 
Gluconeogenesis, 
Carbon fixation in 
photosynthetic 
organisms, 
Biosynthesis of 
antibiotics 
G 
Gene.781  ATP synthase subunit beta -33.54 3.00E-122 C; F; P NA  C 
Gene.784  ATP synthase gamma chain -31.78 6.89E-108 C; F; P NA  C 
Gene.2652  Glucose-6-phosphate isomerase -30.3 3.88E-099 F; P; C Glycolysis / 
Gluconeogenesis, 
Amino sugar and 
nucleotide sugar 
metabolism, Starch 
and sucrose 
metabolism, 
Biosynthesis of 
antibiotics, Pentose 
phosphate pathway 
G 
Gene.675  Elongation factor Tu -29.47 5.95E-119 F; C; P Purine metabolism, 
Thiamine 
metabolism 
J 
Gene.780  ATP synthase subunit alpha -28.77 4.66E-101 C; F; P NA  C 
Gene.2093  Nucleoside diphosphate kinase -27.94 6.68E-120 F; P; C Purine metabolism, 
Pyrimidine 
metabolism, 
Biosynthesis of 
antibiotics 
F 
Gene.2411  Preprotein translocase subunit -27.81 2.78E-108 C NA  U 
Gene.1975  Dipeptidase -27.76 4.79E-121 F; P NA  E 
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Gene.138  Universal stress protein -27.56 4.82E-116 C; P NA  T 
Gene.1851  Lactoylglutathione lyase -27.34 6.22E-104 F; P Pyruvate metabolism E 
Gene.1755  Bee3-like protein -26.91 8.98E-124 F; C NA  M 
Gene.1231  Hypothetical protein -25.37 1.66E-119 NA NA  S 
Gene.1177  Glutamyl-tRNA(Gln) amidotransferase subunit E -24.65 6.57E-101 F Aminoacyl-tRNA 
biosynthesis 
S 
Gene.787  ATP synthase subunit delta -24.36 1.89E-107 C; F; P NA  C 
Gene.1138  Chromosome partition Smc -24.26 4.80E-123 NA NA  S 
Gene.2332 DNA protection during starvation -23.73 0 F; P; C NA  P 
Gene.2579  Sugar ABC transporter ATP-binding protein -21.6 2.21E-030 F; P; C Purine metabolism G 
Gene.1894  Universal stress protein -21.48 1.52E-107 C; P NA  T 
Gene.2173  50S ribosomal L7 L12 -21.04 3.35E-100 F; C; P NA  J 
Gene.1170  General stress protein -19.87 3.81E-112 C NA  S 
Gene.1152  UTP--glucose-1-phosphate uridylyltransferase -19.72 4.25E-110 P: F Galactose 
metabolism, Pentose 
and glucuronate 
interconversions, 
Amino sugar and 
nucleotide sugar 
metabolism, Starch 
and sucrose 
metabolism, 
Biosynthesis of 
antibiotics 
M 
Gene.1616  alpha-glycerophosphate oxidase -19.43 2.26E-048 P; C; F Glycerophospholipid 
metabolism 
C 
Gene.1599  Glutathione peroxidase -19.4 3.66E-096 P; F Glutathione 
metabolism, 
Arachidonic acid 
metabolism 
O 
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Gene.1504  Phosphoenolpyruvate- phosphotransferase -19.11 1.00E-069 C; F; P NA  G 
Gene.1097  Superoxide dismutase -19.08 3.03E-104 F; P NA  P 
Gene.2171  50S ribosomal L10 -18.89 1.04E-108 F; P; C NA  J 
Gene.1622  Glycerol kinase -18.86 3.19E-038 F P Glycerolipid 
metabolism 
C 
Gene.2479  PTS trehalose-specific IIBC component -17.92 1.36E-100 F; P; C NA  G 
Gene.1549  NADH peroxidase -17.53 4.98E-082 C; F; P NA  P 
Gene.367  Cell division protein  -17.43 8.83E-098 P; C NA  D 
Gene.721  2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 
-17.09 9.29E-097 P; F NA  G 
Gene.140  Histidine triad -16.92 6.55E-096 F NA  F, G 
Gene.764  50S ribosomal L17 -16.9 4.46E-088 F; C; P NA  J 
Gene.1490  Large conductance mechanosensitive channel -16.85 4.94E-099 F; P; C NA  M 
Gene.2677  NADH oxidase -16.46 3.74E-048 C; F; P Oxidative 
phosphorylation 
P 
Gene.1900  Pyruvate kinase -16.37 2.73E-039 F; P Glycolysis / 
Gluconeogenesis, 
Purine metabolism, 
Pyruvate 
metabolism, 
Biosynthesis of 
antibiotics 
G 
Gene.118  Foldase -16.08 6.78E-100 F; P; C NA  O 
Gene.1858  Thioredoxin -15.86 4.48E-079 C; F; P NA  O 
Gene.1761  Peptidase (Bee-2) -15.33 2.35E-095 C NA  M 
Gene.2165  Hypothetical protein -15.33 4.10E-071 NA NA  S 
Gene.2143  Lactose-specific phosphotransferase enzyme IIA 
component 
-15.3 6.50E-084 C; F; P NA  G 
Gene.738  Ribosomal S7 -15.13 4.21E-078 F; C; P NA  J 
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Gene.47  Pyruvate dehydrogenase E1 component subunit 
beta 
-14.89 5.27E-083 F; P Glycolysis / 
Gluconeogenesis, 
Pyruvate 
metabolism, Citrate 
cycle (TCA cycle), 
Biosynthesis of 
antibiotics 
C 
Gene.1018  Membrane protein -14.45 1.74E-083 C NA  S 
Gene.2135 Tagatose 1,6-diphosphate aldolase -14.35 1.73E-097 F; P Galactose 
metabolism 
G 
Gene.1136  Phosphoglucomutase -13.61 2.81E-055 F; P Glycolysis / 
Gluconeogenesis, 
Purine metabolism, 
Galactose 
metabolism, 
Streptomycin 
biosynthesis, Amino 
sugar and nucleotide 
sugar metabolism, 
Starch and sucrose 
metabolism, 
Biosynthesis of 
antibiotics, Pentose 
phosphate pathway 
G 
Gene.22  Dihydrolipoamide acetyltransferase -13.58 2.18E-084 P; F NA  C 
Gene.1559  Galactokinase -13.36 1.26E-068 F; C; P Galactose 
metabolism, Amino 
sugar and nucleotide 
sugar metabolism 
G 
Gene.658  Pyruvate oxidase -13.35 9.57E-073 F; P Pyruvate metabolism E 
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Gene.1039  Tyrosine decarboxylase -13.23 1.86E-084 F; P Tyrosine 
metabolism, 
Isoquinoline alkaloid 
biosynthesis, 
Methane metabolism 
E 
Gene.29  Dihydrolipoyl dehydrogenase -13.08 2.65E-085 C; F; P Glycine, serine and 
threonine 
metabolism, 
Glycolysis / 
Gluconeogenesis, 
Propanoate 
metabolism, 
Pyruvate 
metabolism, Citrate 
cycle (TCA cycle), 
Valine, leucine and 
isoleucine 
degradation, 
Biosynthesis of 
antibiotics 
C 
Gene.1713  Transketolase -12.87 6.07E-056 F; P Biosynthesis of 
ansamycins, Carbon 
fixation in 
photosynthetic 
organisms, 
Biosynthesis of 
antibiotics, Pentose 
phosphate pathway 
G 
Gene.1414 Hypothetical protein -12.84 2.45E-094 C NA  S 
Gene.607  ABC transporter permease -12.31 5.79E-086 C; P NA  E 
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Gene.2140  Galactose-6-phosphate isomerase subunit lacB -12.3 1.43E-079 F; P Galactose 
metabolism 
G 
Gene.734  50S ribosomal L5 -12.3 9.28E-071 F; C; P NA  J 
Gene.2292  DNA-directed RNA polymerase subunit beta -12.2 1.26E-074 F; P Purine metabolism, 
Pyrimidine 
metabolism 
K 
Gene.1941  Hypothetical protein -12.12 1.26E-065 C NA  S 
Gene.139  Regulatory Spx -12.04 0 P; C NA  K 
Gene.1530  Ribose-5-phosphate isomerase -11.91 1.28E-026 F NA  S 
Gene.348  Cell division protein -11.91 7.10E-070 F; P; C NA  D 
Gene.1978  Ribosomal S1 -11.81 4.46E-057 F; C; P NA  J 
Gene.2160  50S ribosomal L1 -11.75 1.24E-076 P; F C NA  J 
Gene.622  Formate acetyltransferase -11.55 7.70E-031 P; C; F Propanoate 
metabolism, 
Pyruvate 
metabolism, 
Butanoate 
metabolism 
C 
Gene.1322  Trypsin-like serine protease  -11.24 7.82E-081 P; C; F NA  S 
Gene.872  Orotate phosphoribosyltransferase -11.21 2.41E-054 F; P Drug metabolism - 
other enzymes, 
Pyrimidine 
metabolism 
F 
Gene.370  YggS family pyridoxal phosphate enzyme -11.11 7.03E-062 F D-Alanine 
metabolism 
F 
Gene.1427  Transcription antitermination factor -11.05 1.65E-073 F; P NA  K 
Gene.652  Elongation factor G -10.92 9.04E-063 F; C; P NA  J 
Gene.1147  Glycerol-3-phosphate dehydrogenase -10.74 1.81E-079 P; C; F Glycerophospholipid 
metabolism 
C 
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Gene.1528  Acetyl- biotin carboxyl carrier -10.68 1.62E-061 F; P; C Fatty acid 
biosynthesis, 
Tetracycline 
biosynthesis, 
Propanoate 
metabolism, 
Aflatoxin 
biosynthesis, Carbon 
fixation pathways in 
prokaryotes, 
Pyruvate 
metabolism, 
Biosynthesis of 
antibiotics 
I 
Gene.810  LacI family transcriptional regulator -10.63 8.14E-076 F; P NA  K 
Gene.1303  50S ribosomal L19 -10.49 8.77E-075 F; C; P NA  J 
Gene.1400  ATP-binding protein -10.45 3.55E-083 C NA  S 
Gene.788  ATP synthase subunit B -10.41 2.34E-076 C; F; P NA  C 
Gene.1323  General stress protein -10.23 3.89E-075 NA NA  S 
Gene.2389  Aldehyde-alcohol dehydrogenase -10.15 4.47E-053 F; P Glycine, serine and 
threonine 
metabolism, 
Tyrosine 
metabolism, Retinol 
metabolism, Fatty 
acid degradation, 
Butanoate 
metabolism, 
Biosynthesis of 
antibiotics, Benzoate 
C 
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degradation, Dioxin 
degradation, alpha-
Linolenic acid 
metabolism, 
Metabolism of 
xenobiotics by 
cytochrome P450, 
Naphthalene 
degradation, 
Chloroalkane and 
chloroalkene 
degradation, 
Glycolysis / 
Gluconeogenesis, 
Xylene degradation, 
Pyruvate 
metabolism, 
Phenylalanine 
metabolism, Drug 
metabolism - 
cytochrome P450 
Gene.749  50S ribosomal L6 -10.12 3.80E-072 F; C; P NA  J 
Gene.809  UDP-glucose 4-epimerase -10.12 1.32E-067 F; C; P Galactose 
metabolism, Amino 
sugar and nucleotide 
sugar metabolism 
M 
Gene.38  Pyruvate dehydrogenase (acetyl-transferring) E1 
alpha subunit 
-10.05 1.80E-079 F; P Glycolysis / 
Gluconeogenesis, 
Pyruvate 
metabolism, Citrate 
C 
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cycle (TCA cycle), 
Biosynthesis of 
antibiotics 
Gene.472  Alpha,alpha-phosphotrehalase -9.96 3.08E-070 C; P; F Starch and sucrose 
metabolism 
G 
Gene.773  50S ribosomal L24 -9.87 6.75E-070 F; C; P NA  J 
Gene.1140  Metal ion (Mn2+ Fe2+) transporter  -9.78 3.34E-054 C; P; F NA  P 
Gene.467  N-acetylmuramoyl-L-alanine amidase -9.76 3.19E-077 F; P Tryptophan 
metabolism, 
Aminobenzoate 
degradation, 
Arginine and proline 
metabolism, Styrene 
degradation, 
Phenylalanine 
metabolism 
N, U 
Gene.737  30S ribosomal S5 -9.68 4.80E-070 F; C; P NA  J 
Gene.1500  ATP-dependent Clp protease ATP-binding subunit -9.66 6.38E-046 F; P NA  O 
Gene.2077  GNAT family acetyltransferase -9.66 1.31E-073 F NA  S 
Gene.122  Aldo keto reductase -9.49 2.28E-075 F; P NA  C 
Gene.1696  Uracil phosphoribosyltransferase -9.47 2.68E-041 F; P Pyrimidine 
metabolism 
F 
Gene.1360  ATP-dependent metallopeptidase -9.43 6.71E-031 F; P; C Purine metabolism O 
Gene.2136  Tagatose-6-phosphate kinase -9.42 4.54E-079 F; P Galactose 
metabolism 
G 
Gene.1439  Hypothetical protein -9.38 2.45E-084 NA NA  S 
Gene.1752  VWA domain-containing (Bee-1) -9.15 1.76E-071 C NA  S 
Gene.1405  Fructose-bisphosphate aldolase -9.14 1.14E-058 F; P Glycolysis / 
Gluconeogenesis, 
Fructose and 
G 
 150 
mannose 
metabolism, Carbon 
fixation in 
photosynthetic 
organisms, Methane 
metabolism, 
Biosynthesis of 
antibiotics, Pentose 
phosphate pathway 
Gene.1318  Cell division protein -9.04 1.91E-077 P; C NA  D 
Gene.2133  PTS system lactose-specific EIICB component -9.02 1.61E-073 F; C; P NA  G 
Gene.1630  Tyrosine--tRNA ligase -8.91 4.41E-063 F; P; C Aminoacyl-tRNA 
biosynthesis 
J 
Gene.166  Hypothetical protein -8.87 8.98E-016 NA NA  S 
Gene.342  Glucose-6-phosphate dehydrogenase -8.87 1.10E-061 F Ubiquinone and 
other terpenoid-
quinone 
biosynthesis, 
Benzoate 
degradation 
S 
Gene.105  Oligoendopeptidase F -8.85 4.67E-071 P; F NA  E 
Gene.1743  CAAX amino terminal protease -8.85 1.74E-071 P; C; F NA  S 
Gene.1636  MIP family channel -8.84 4.29E-025 C; P; F NA  G 
Gene.2467  ATP-dependent Clp protease proteolytic subunit -8.49 6.94E-072 C; P; F NA  O 
Gene.2501  Hypothetical protein -8.44 1.92E-027 NA NA  NA 
Gene.293  Alpha3-beta1 integrin-binding family -8.43 3.27E-057 F NA  S 
Gene.377  S4 domain-containing protein -8.41 1.30E-074 F; C NA  J 
Gene.1291  Flavin reductase -8.4 2.32E-069 F; P Riboflavin 
metabolism 
S 
Gene.2232  Universal stress -8.38 3.95E-061 C; P NA  T 
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Gene.1515  Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta 
-8.36 1.10E-066 F; P; C Fatty acid 
biosynthesis, 
Tetracycline 
biosynthesis, 
Propanoate 
metabolism, 
Aflatoxin 
biosynthesis, Carbon 
fixation pathways in 
prokaryotes, 
Pyruvate 
metabolism, 
Biosynthesis of 
antibiotics 
I 
Gene.1053  Zinc-containing alcohol dehydrogenase -8.34 6.36E-075 F; P Metabolism of 
xenobiotics by 
cytochrome P450, 
Naphthalene 
degradation, 
Glycine, serine and 
threonine 
metabolism, 
Chloroalkane and 
chloroalkene 
degradation, 
Glycolysis / 
Gluconeogenesis, 
Tyrosine 
metabolism, Retinol 
metabolism, Fatty 
C 
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acid degradation, 
Drug metabolism - 
cytochrome P450, 
Methane 
metabolism, 
Biosynthesis of 
antibiotics, alpha-
Linolenic acid 
metabolism 
Gene.1526  MarR family transcriptional regulator -8.3 1.07E-069 F; P NA  K 
Gene.735  Single-stranded DNA-binding protein -8.3 1.99E-073 P; F NA  L 
Gene.798  Arginyl-tRNA synthetase -8.28 2.03E-071 F; C; P Aminoacyl-tRNA 
biosynthesis 
J 
Gene.1397  Virion core protein -8.21 1.56E-070 NA NA  S 
Gene.851  Carboxypeptidase Taq metallopeptidase -8.14 6.21E-055 F; P NA  E 
Gene.785  ATP synthase subunit A -8.1 5.44E-068 C; F; P NA  C 
Gene.1174  General stress protein -8.08 1.25E-069 C NA  S 
Gene.707  50S ribosomal L2 -8.08 1.17E-058 F; C; P NA  J 
Gene.2405  Integral membrane protein -8.07 4.82E-075 C NA  S 
Gene.980  Penicillin-binding protein -8.07 1.00E-068 C; P; F NA  M 
Gene.1111  dTDP-glucose 4,6-dehydratase -8.03 2.40E-034 F; P Polyketide sugar unit 
biosynthesis, 
Acarbose and 
validamycin 
biosynthesis, 
Biosynthesis of 
vancomycin group 
antibiotics, 
Streptomycin 
biosynthesis, 
M 
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Biosynthesis of 
antibiotics 
Gene.742  50S ribosomal L15 -7.94 1.61E-061 F; C; P NA  J 
Gene.1744  NADH-flavin reductase -7.81 1.91E-089 F; P Riboflavin 
metabolism 
S 
Gene.378  Cell division protein -7.79 4.07E-035 P; C NA  S 
Gene.1168  Phosphate transport system regulatory -7.76 1.02E-067 P; C NA  P 
Gene.1558  Tellurite resistance protein TelA -7.76 8.19E-072 NA NA  P 
Gene.1863  Hypothetical protein -7.66 1.60E-067 NA NA  S 
Gene.1502  Threonine--tRNA ligase -7.6 1.38E-057 F; C; P Aminoacyl-tRNA 
biosynthesis 
J 
Gene.799  Galactose-1-phosphate uridylyltransferase -7.57 4.02E-066 C; P; F Galactose 
metabolism, Amino 
sugar and nucleotide 
sugar metabolism 
G 
Gene.2329  Hypothetical protein -7.51 2.25E-065 NA NA  S 
Gene.87  Ribosomal S17 -7.5 3.28E-082 C NA  S 
Gene.2259  Lipid kinase -7.46 1.16E-034 F; P Nicotinate and 
nicotinamide 
metabolism, 
Phosphatidylinositol 
signaling system, 
Glycerophospholipid 
metabolism, 
Glycerolipid 
metabolism 
I 
Gene.2726  Bifunctional AAC/APH aminoglycoside modifying 
enzyme 
-7.37 4.08E-065 F; C; P NA  S 
Gene.650  DNA gyrase subunit A -7.21 1.65E-066 F; C; P NA  L 
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Gene.114  Acetate kinase -7.16 2.27E-058 F; P; C Taurine and 
hypotaurine 
metabolism, 
Propanoate 
metabolism, Carbon 
fixation pathways in 
prokaryotes, 
Pyruvate 
metabolism, 
Methane metabolism 
C 
Gene.2017  Hypothetical protein -7.15 0 NA NA  NA 
Gene.86  Hypothetical Cytosolic -7.13 3.75E-064 C NA  S 
Gene.1196  Amino acid ABC transporter ATP-binding -7.1 6.41E-033 F; P NA  E 
Gene.1272  Hypothetical protein -7.1 1.19E-048 NA NA  NA 
Gene.1022  Transcriptional regulator -7.09 6.25E-072 NA NA  K 
Gene.1232  NAD dependent epimerase dehydratase family -7.07 2.98E-066 P; F NA  G, M 
Gene.1505  Acetyl- biotin carboxylase subunit -7.01 1.58E-033 F Fatty acid 
biosynthesis, 
Tetracycline 
biosynthesis, 
Propanoate 
metabolism, 
Aflatoxin 
biosynthesis, Carbon 
fixation pathways in 
prokaryotes, 
Pyruvate 
metabolism, 
Biosynthesis of 
antibiotics 
I 
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Gene.1877  Elongation factor Tu -7.01 8.60E-043 F; C; P NA  J 
Gene.1691  Adenosylcobyric acid synthase -6.94 1.90E-034 P; F Porphyrin and 
chlorophyll 
metabolism 
S 
Gene.1351  Ribonucleotide-diphosphate reductase subunit beta -6.89 2.13E-059 F; P; C Purine metabolism, 
Glutathione 
metabolism, 
Pyrimidine 
metabolism 
F 
Gene.1977  Hypothetical protein -6.87 2.15E-062 NA NA  S 
Gene.727  30S ribosomal S3 -6.87 1.01E-044 F; C; P NA  J 
Gene.1844  Holiday junction resolvase -6.86 3.10E-041 F; P; C NA  L 
Gene.83  Membrane protein -6.86 8.28E-064 C NA  S 
Gene.605  Glycine betaine carnitine choline ABC transporter -6.81 4.68E-046 P; F NA  M 
Gene.885  Membrane protein -6.79 9.71E-058 C NA  NA 
Gene.111  Cytochrome P450 -6.74 3.59E-067 F; P NA  Q 
Gene.1438  Ribosomal protein -6.74 6.84E-066 C NA  J 
Gene.2616  UDP-glucose 4-epimerase -6.67 9.86E-035 F NA  M 
Gene.2141  Galactose-6-phosphate isomerase subunit LacA -6.59 6.82E-046 F; P: Galactose 
metabolism 
G 
Gene.1235  Asparagine--tRNA ligase -6.58 1.23E-021 F; C; P Aminoacyl-tRNA 
biosynthesis 
J 
Gene.1037  Calcium-translocating P-type PMCA-type -6.48 4.41E-064 F; C NA  P 
Gene.821  30S ribosomal S2 -6.46 3.65E-033 F; C; P NA  J 
Gene.838  Ribosome-binding factor A -6.46 2.79E-043 C; P NA  J 
Gene.1208  GTP cyclohydrolase -6.45 9.30E-062 F NA  S 
Gene.1565  Aldose 1-epimerase -6.41 1.53E-020 P; F Glycolysis / 
Gluconeogenesis, 
Galactose 
G 
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metabolism, 
Biosynthesis of 
antibiotics 
Gene.271  PTS Fru IIC component -6.37 2.90E-021 P; C; F  NA  G 
Gene.1996  Hypothetical protein -6.33 1.33E-061 NA NA  S 
Gene.1403  Lipoyltransferase and lipoate- ligase -6.32 5.40E-025 F; P NA  H 
Gene.672  Preprotein translocase subunit -6.31 1.71E-031 P; C NA  U 
Gene.147  Hypothetical protein -6.29 2.51E-045 NA NA  S 
Gene.608  Glycine betaine carnitine choline ABC transporter 
permease 
-6.29 3.34E-028 C; P NA  E 
Gene.1652  Dihydroxyacetone phosphotransfer subunit -6.25 7.63E-062 C; P; F NA  G 
Gene.751  30S ribosomal S8 -6.25 4.45E-030 F; C; P NA  J 
Gene.1980  3-dehydroquinate synthase -6.19 2.79E-045 NA NA  NA 
Gene.1216  Glycyl-tRNA synthetase beta subunit -6.13 4.65E-034 F; P; C Aminoacyl-tRNA 
biosynthesis 
J 
Gene.1425  PTS mannose fructose sorbose IIB component -6.08 9.09E-033 C; P; F NA  G 
Gene.1363  Secreated antigen SagA -6.07 7.34E-024 NA NA  M 
Gene.934  Peptidase -6.07 1.15E-070 NA NA  NA 
Gene.419  Dipeptidase -6.05 1.47E-029 F; P: NA  E 
Gene.747  30S ribosomal S12 -6.03 1.50E-030 F; C; P NA  J 
 
1C, cellular component; P, biological process; F, molecular function; NA, not applicable 
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2[D] Cell cycle control, cell division, chromosome partitioning; [M] Cell wall/membrane/envelope biogenesis; [N] Cell motility; [O] Post-translational 
modification, protein turnover & chaperones; [T] Signal transduction mechanisms; [U] Intracellular trafficking, secretion & vesicular transport; [V] 
Defense mechanisms; [J] Translation, ribosomal structure & biogenesis; [K] Transcription; [L] Replication, recombination & repair; [C] Energy 
production & conversion; [G] Carbohydrate transport & metabolism; [E] Amino acid transport & metabolism; [F] Nucleotide transport & metabolism; 
[H] Coenzyme transport & metabolism; [I] Lipid transport & metabolism; [Q] Secondary metabolites biosynthesis, transport & catabolism; [P] 
Inorganic ion transport & metabolism; [S] Function unknown 
 
 
 
 
 
